{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 0, "source_chunk_idxs": [0], "num_tokens": 494, "text": "Frontiers | Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nFrontiers in Molecular Biosciences\nAbout us\nAbout us\n- Who we are\n- Mission and values\n- History\n- Leadership\n- Awards\n- Impact and progress\n- Frontiers' impact\n- Our annual reports\n- Publishing model\n- How we publish\n- Open access\n- Peer review\n- Research integrity\n- Research Topics\n- FAIR\u00b2 Data Management\n- Fee policy\n- Services\n- Societies\n- National consortia\n- Institutional partnerships\n- Collaborators\n- More from Frontiers\n- Frontiers Forum\n- Frontiers Planet Prize\n- Press office\n- Sustainability\n- Career opportunities\n- Contact us\nAll journals\nAll articles\nSubmit your research\nSearch\nFrontiers in Molecular Biosciences\nSections\nSections\n- Bioenergetics\n- Biological Modeling and Simulation\n- Cellular Biochemistry\n- Genome Organization and Dynamics\n- Glycoscience\n- Lipids, Membranes and Membranous Organelles\n- Metabolomics\n- Micronutrient Biology\n- Molecular Biophysics\n- Molecular Diagnostics and Therapeutics\n- Molecular Evolution\n- Molecular Recognition\n- Nanobiotechnology\n- Protein Biochemistry for Basic and Applied Sciences\n- RNA Networks and Biology\n- Structural Biology\nArticles\nResearch Topics\nEditorial board\nAbout journal\nAbout journal\n- Scope\n- Field chief editors\n- Mission &amp; scope\n- Facts\n- Journal sections\n- Open access statement\n- Copyright statement\n- Quality\n- For authors\n- Why submit?\n- Article types\n- Author guidelines\n- Editor guidelines\n- Publishing fees\n- Submission checklist\n- Contact editorial office\nAbout us\nAbout us\n- Who we are\n- Mission and values\n- History\n- Leadership\n- Awards\n- Impact and progress\n- Frontiers' impact\n- Our annual reports\n- Publishing model\n- How we publish\n- Open access\n- Peer review\n- Research integrity\n- Research Topics\n- FAIR\u00b2 Data Management\n- Fee policy\n- Services\n- Societies\n- National consortia\n- Institutional partnerships\n- Collaborators\n- More from Frontiers\n- Frontiers Forum\n- Frontiers Planet Prize\n- Press office\n- Sustainability\n- Career opportunities\n- Contact us\nAll journals\nAll articles\nSubmit your research\nFrontiers in Molecular Biosciences\nSections\nSections\n- Bioenergetics\n- Biological Modeling and Simulation\n- Cellular Biochemistry\n- Genome Organization and Dynamics\n- Glycoscience\n- Lipids, Membranes and Membranous Organelles\n- Metabolomics\n- Micronutrient Biology\n- Molecular Biophysics\n- Molecular Diagnostics and Therapeutics\n- Molecular Evolution\n- Molecular Recognition\n- Nanobiotechnology\n- Protein Biochemistry for Basic and Applied Sciences\n- RNA Networks and Biology\n- Structural Biology\nArticles\nResearch Topics\nEditorial board\nAbout journal\nAbout journal", "doc_items_refs": ["#/texts/1", "#/texts/2", "#/texts/3", "#/texts/4", "#/texts/5", "#/texts/6", "#/texts/7", "#/texts/8", "#/texts/9", "#/texts/10", "#/texts/11", "#/texts/12", "#/texts/13", "#/texts/14", "#/texts/15", "#/texts/16", "#/texts/17", "#/texts/18", "#/texts/19", "#/texts/20", "#/texts/21", "#/texts/22", "#/texts/23", "#/texts/24", "#/texts/25", "#/texts/26", "#/texts/27", "#/texts/28", "#/texts/29", "#/texts/30", "#/texts/31", "#/texts/32", "#/texts/33", "#/texts/34", "#/texts/35", "#/texts/36", "#/texts/37", "#/texts/38", "#/texts/39", "#/texts/40", "#/texts/41", "#/texts/42", "#/texts/43", "#/texts/44", "#/texts/45", "#/texts/46", "#/texts/47", "#/texts/48", "#/texts/49", "#/texts/50", "#/texts/51", "#/texts/52", "#/texts/53", "#/texts/54", "#/texts/55", "#/texts/56", "#/texts/57", "#/texts/58", "#/texts/59", "#/texts/60", "#/texts/61", "#/texts/62", "#/texts/63", "#/texts/64", "#/texts/65", "#/texts/66", "#/texts/67", "#/texts/68", "#/texts/69", "#/texts/70", "#/texts/71", "#/texts/72", "#/texts/73", "#/texts/74", "#/texts/75", "#/texts/76", "#/texts/77", "#/texts/78", "#/texts/79", "#/texts/80", "#/texts/81", "#/texts/82", "#/texts/83", "#/texts/84", "#/texts/85", "#/texts/86", "#/texts/87", "#/texts/88", "#/texts/89", "#/texts/90", "#/texts/91", "#/texts/92", "#/texts/93", "#/texts/94", "#/texts/95", "#/texts/96", "#/texts/97", "#/texts/98", "#/texts/99", "#/texts/100", "#/texts/101", "#/texts/102", "#/texts/103", "#/texts/104", "#/texts/105", "#/texts/106", "#/texts/107", "#/texts/108", "#/texts/109", "#/texts/110", "#/texts/111", "#/texts/112", "#/texts/113", "#/texts/114", "#/texts/115", "#/texts/116", "#/texts/117", "#/texts/118", "#/texts/119", "#/texts/120", "#/texts/121", "#/texts/122", "#/texts/123", "#/texts/124", "#/texts/125", "#/texts/126", "#/texts/127", "#/texts/128", "#/texts/129", "#/texts/130", "#/texts/131", "#/texts/132"], "page_nos": [], "uuid": "0c3ff761-ddb2-4c86-9727-46b77f13fc11"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 1, "source_chunk_idxs": [1], "num_tokens": 354, "text": "Frontiers | Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\n- Scope\n- Field chief editors\n- Mission &amp; scope\n- Facts\n- Journal sections\n- Open access statement\n- Copyright statement\n- Quality\n- For authors\n- Why submit?\n- Article types\n- Author guidelines\n- Editor guidelines\n- Publishing fees\n- Submission checklist\n- Contact editorial office\nFrontiers in Molecular Biosciences\nSections\nSections\n- Bioenergetics\n- Biological Modeling and Simulation\n- Cellular Biochemistry\n- Genome Organization and Dynamics\n- Glycoscience\n- Lipids, Membranes and Membranous Organelles\n- Metabolomics\n- Micronutrient Biology\n- Molecular Biophysics\n- Molecular Diagnostics and Therapeutics\n- Molecular Evolution\n- Molecular Recognition\n- Nanobiotechnology\n- Protein Biochemistry for Basic and Applied Sciences\n- RNA Networks and Biology\n- Structural Biology\nArticles\nResearch Topics\nEditorial board\nAbout journal\nAbout journal\n- Scope\n- Field chief editors\n- Mission &amp; scope\n- Facts\n- Journal sections\n- Open access statement\n- Copyright statement\n- Quality\n- For authors\n- Why submit?\n- Article types\n- Author guidelines\n- Editor guidelines\n- Publishing fees\n- Submission checklist\n- Contact editorial office\nSubmit your research\nSearch\nYour new experience awaits. Try the new design now and help us make it even better\nSwitch to the new experience\nREVIEW article\nFront. Mol. Biosci. , 26 June 2025\nSec. Molecular Diagnostics and Therapeutics\nVolume 12 - 2025 |\nhttps://doi.org/10.3389/fmolb.2025.1622186\nThis article is part of the Research Topic Estrogens and Neurodegeneration: a Link Between Menopause and Alzheimer's Diseases in Women\nView all 5 articles", "doc_items_refs": ["#/texts/133", "#/texts/134", "#/texts/135", "#/texts/136", "#/texts/137", "#/texts/138", "#/texts/139", "#/texts/140", "#/texts/141", "#/texts/142", "#/texts/143", "#/texts/144", "#/texts/145", "#/texts/146", "#/texts/147", "#/texts/148", "#/texts/149", "#/texts/150", "#/texts/151", "#/texts/152", "#/texts/153", "#/texts/154", "#/texts/155", "#/texts/156", "#/texts/157", "#/texts/158", "#/texts/159", "#/texts/160", "#/texts/161", "#/texts/162", "#/texts/163", "#/texts/164", "#/texts/165", "#/texts/166", "#/texts/167", "#/texts/168", "#/texts/169", "#/texts/170", "#/texts/171", "#/texts/172", "#/texts/173", "#/texts/174", "#/texts/175", "#/texts/176", "#/texts/177", "#/texts/178", "#/texts/179", "#/texts/180", "#/texts/181", "#/texts/182", "#/texts/183", "#/texts/184", "#/texts/185", "#/texts/186", "#/texts/187", "#/texts/188", "#/texts/189", "#/texts/190", "#/texts/191", "#/texts/192", "#/texts/193", "#/texts/194", "#/texts/195", "#/texts/196", "#/texts/197", "#/texts/198", "#/texts/199"], "page_nos": [], "uuid": "85e7bbfb-2c70-4110-bebc-869440eee0fd"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 2, "source_chunk_idxs": [2], "num_tokens": 497, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nFernando Lizcano\n1,2,3,4\n* Daniela Sanabria\n3,4\nEliana Aviles\n3,4\n- 1\nCenter of Biomedical Investigation (CIBUS), Universidad de La Sabana, Ch\u00eda, Colombia\n- 2\nSchool of Medicine, Universidad de La Sabana, Ch\u00eda, Colombia\n- 3\nFundaci\u00f3n Cardioinfantil-Instituto de Cardiolog\u00eda, Bogot\u00e1, Colombia\n- 4\nSchool of Medicine, Universidad del Rosario, Bogot\u00e1, Colombia\nAlzheimer's disease (AD) is the most prevalent cause of dementia worldwide, disproportionately affecting women and lacking effective disease-modifying therapies. While traditional approaches have focused on amyloid \u03b2 (A\u03b2) plaques and tau pathology, emerging evidence highlights the role of metabolic dysfunction, mitochondrial impairment, and hormonal signaling in the pathogenesis of AD. Estrogens exert neuroprotective effects by modulating synaptic plasticity, enhancing mitochondrial bioenergetics, and reducing oxidative stress and inflammation. Similarly, glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for the treatment of type 2 diabetes, have demonstrated promising cognitive benefits, potentially mediated through improved insulin signaling, neuronal survival, and reduced \u03b2-amyloid (A\u03b2) and tau burden. This review explores the converging mechanisms through which estrogens and GLP-1RAs may act synergistically to prevent or delay the onset of AD. We examine the influence of sex differences in mitochondrial dynamics, estrogen receptor distribution, and GLP-1 signaling pathways, particularly within central nervous system regions implicated in AD. Preclinical studies using GLP-1-estrogen conjugates have shown enhanced metabolic and neuroprotective outcomes, accompanied by reduced systemic hormonal exposure, suggesting a viable therapeutic strategy. As the global prevalence of AD continues to rise, especially among postmenopausal women, dual agonism targeting estrogen and GLP-1 receptors may represent a novel, physiologically informed approach to prevention and intervention. Ongoing clinical trials and future research must consider sex-specific factors, receptor polymorphisms, and brain-region selectivity to optimize the translational potential of this combined strategy.", "doc_items_refs": ["#/texts/201", "#/texts/202", "#/texts/203", "#/texts/204", "#/texts/205", "#/texts/206", "#/texts/207", "#/texts/208", "#/texts/209", "#/texts/210", "#/texts/211"], "page_nos": [], "uuid": "ec7b6edb-8dfc-4c92-9a06-3173305737cc"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 3, "source_chunk_idxs": [3], "num_tokens": 477, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\n1 Introduction\nAlzheimer's disease (AD) represents the most prevalent form of dementia to date. According to the World Health Organization (WHO), over 55 million people worldwide live with some form of dementia, with approximately 10 million new cases reported each year. The prevalence of this condition varies by gender, with an estimated 8.1% of women and 5.4% of men over the age of 65 experiencing some form of dementia, nearly 70% of which corresponds to Alzheimer's disease (AD) (\nLivingston et al., 2020\n;\nMontero-Odasso et al., 2020\n;\nOMS, 2021\n).\nThe etiology of AD is complex and multifactorial, characterized by progressive neuronal aging, synaptic loss, and dysfunction of neural networks (\nKnopman et al., 2021\n). Pathologically, AD is marked by the extracellular accumulation of \u03b2-amyloid (A\u03b2) plaques and intracellular neurofibrillary tangles composed of hyperphosphorylated tau (\u03c4) protein (\nShi et al., 2020\n). A\u03b2 plaques originate from the aberrant processing of amyloid precursor protein (APP), mediated sequentially by \u03b2- and \u03b3-secretases. This cleavage generates the membrane-bound C-terminal fragment CTF99, which is subsequently processed by \u03b3-secretase to release A\u03b2 peptides of 40-42 amino acids (\nNeha and Parvez, 2023\n). The aggregation of these peptides into oligomers and their subsequent deposition as extracellular senile plaques is facilitated by interactions with apolipoproteins and proteoglycans, contributing to the synaptic dysfunction and neurodegeneration that define the disease (\nArjmand et al., 2024\n).\nAdditionally, the hyperphosphorylation of tau protein disrupts its binding to neuronal microtubules. Hyperphosphorylated tau induces the formation of insoluble protein aggregates and, ultimately, intracellular tangles. This abnormal accumulation interferes with axonal transport and promotes axonal degeneration (\nKinney et al., 2018\n).", "doc_items_refs": ["#/texts/213", "#/texts/214", "#/texts/215", "#/texts/216", "#/texts/217", "#/texts/218", "#/texts/219", "#/texts/220", "#/texts/221", "#/texts/222", "#/texts/223", "#/texts/224", "#/texts/225", "#/texts/226", "#/texts/227", "#/texts/228", "#/texts/229", "#/texts/230", "#/texts/231"], "page_nos": [], "uuid": "51b15de9-a2a5-4818-ae1a-e4c06f96697e"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 4, "source_chunk_idxs": [4], "num_tokens": 495, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\n1 Introduction\nTherapeutic efforts aimed at neutralizing these pathological processes have thus far yielded limited results. Monoclonal antibodies targeting A\u03b2, such as aducanumab, lecanemab, and donanemab, have not demonstrated clinically meaningful efficacy (\nTerao and Kodama, 2024\n). Antibodies directed against tau protein, including semorinemab, tilavonemab, and gosuranemab, have shown unpromising preliminary results and fail to improve global patient functionality (\nFlorian et al., 2023\n;\nMonteiro et al., 2023\n). In general, these treatments only modestly reduce disease progression, and their clinical application remains limited due to a lack of effectiveness (\nLivingston et al., 2020\n;\nWalsh et al., 2021\n;\nvan Dyck et al., 2023\n).\nFor these reasons, recent investigations have expanded the focus to additional disease mechanisms. Notably, alterations in cholinergic signaling, neuroinflammation involving microglial activation, and calcium dysregulation have emerged as relevant contributors to AD pathogenesis. Moreover, increasing attention has been given to metabolic dysfunction, particularly in glucose metabolism and the bioenergetic role of estrogens, as potentially essential triggers of AD. Recent research has highlighted the therapeutic potential of glucagon-like peptide-1 receptor agonists (GLP-1RAs) beyond glucose metabolism, particularly in neurodegenerative diseases such as Alzheimer's disease (AD). These agents have demonstrated neuroprotective effects, including the reduction of oxidative stress, enhancement of mitochondrial function, and attenuation of neuroinflammation. Furthermore, emerging evidence suggests that GLP-1RAs may modulate central insulin signaling and synaptic plasticity, pathways that are increasingly implicated in the pathophysiology of AD. In this context, exploring the mechanistic relationship between GLP-1 receptor activation and mitochondrial function in the brain may provide valuable insights into novel therapeutic strategies for AD (\nLiang et al., 2024\n).\nThis review highlights estrogens' role in the central nervous system, with emphasis on their regulatory functions in mitochondrial metabolism. It also explores their potential as a pharmacological target for AD prevention.", "doc_items_refs": ["#/texts/232", "#/texts/233", "#/texts/234", "#/texts/235", "#/texts/236", "#/texts/237", "#/texts/238", "#/texts/239", "#/texts/240", "#/texts/241", "#/texts/242", "#/texts/243", "#/texts/244", "#/texts/245", "#/texts/246", "#/texts/247", "#/texts/248"], "page_nos": [], "uuid": "9b31b76a-42da-4a3d-b074-ce2ef8982c7a"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 5, "source_chunk_idxs": [5], "num_tokens": 459, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\n2 Neuronal metabolism and Alzheimer's disease\nNeurons are subject to systemic metabolic regulatory processes involving carbohydrates and lipids. Metabolic disturbances that elevate cardiovascular risk also affect the cerebral microvasculature, contributing to cognitive decline and the development of dementia, including AD. Impaired cerebral perfusion compromises white matter integrity, deteriorates neural connectivity, and facilitates neurodegenerative processes (\nKellar and Craft, 2020\n;\nHernandez-Rodriguez et al., 2022\n).\nThe metabolic events most closely associated with AD include insulin resistance, hyperglycemia, lipid dysregulation, mitochondrial dysfunction, and oxidative stress. All these factors promote disease progression. While the exact mechanisms remain incompletely understood, type 2 diabetes mellitus (T2DM) is strongly linked to the pathogenesis of AD (\nMittal and Katare, 2016\n). Both conditions share overlapping pathological mechanisms that impair cognitive function, eventually leading to A\u03b2 deposition in the brain. Furthermore, chronic inflammation, oxidative stress, dyslipidemia, mitochondrial dysfunction, impaired insulin signaling, and synaptic dysfunction are all common features of T2DM and AD (\nKapogiannis et al., 2019\n;\nBernabe-Ortiz and Carrillo-Larco, 2022\n).\nAt the molecular level, central or peripheral insulin resistance can result from reduced insulin receptor expression, decreased binding affinity, and disruption of downstream signaling pathways (\nTatar et al., 2003\n). Insulin exerts its cellular effects through two primary pathways: the mitogen-activated protein kinase (MAPK) pathway and the phosphatidylinositol 3-kinase (PI3K)-Akt pathway, the latter of which plays a crucial role in cell growth and survival. Insulin receptor activation triggers the recruitment of insulin receptor substrate (IRS) proteins, which, when phosphorylated on tyrosine residues, activate PI3K-Akt signaling. In contrast, serine phosphorylation of IRS proteins inhibits this signaling cascade (\nCraft and Watson, 2004\n).", "doc_items_refs": ["#/texts/250", "#/texts/251", "#/texts/252", "#/texts/253", "#/texts/254", "#/texts/255", "#/texts/256", "#/texts/257", "#/texts/258", "#/texts/259", "#/texts/260", "#/texts/261", "#/texts/262", "#/texts/263", "#/texts/264", "#/texts/265", "#/texts/266"], "page_nos": [], "uuid": "21d6ddc7-9f72-4b8f-ac75-b9713854b145"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 6, "source_chunk_idxs": [6], "num_tokens": 396, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\n2 Neuronal metabolism and Alzheimer's disease\nThe ratio of serine-phosphorylated IRS to total IRS is widely used as a biomarker of insulin resistance in both brain and peripheral tissues. An elevated ratio reflects greater insulin resistance. Studies have demonstrated cerebral insulin resistance in AD patients using\nex vivo\ninsulin stimulation and measurement of this ratio in brain tissue (\nBassil et al., 2014\n).\nConsequently, impaired insulin sensitivity reduces PI3K-Akt activation and downstream phosphorylation of proteins essential for neuronal survival, such as glycogen synthase kinase-3\u03b2 (GSK3\u03b2). This promotes tau hyperphosphorylation and neurofibrillary tangle formation, hallmark features of AD. Additionally, defective insulin signaling contributes to neuronal energy deficits by decreasing glucose uptake and reducing the expression and function of glucose transporters GLUT3 and GLUT4 in the central nervous system (\nSchulingkamp et al., 2000\n).\nMoreover, reduced cerebral vascularization observed in T2DM leads to chronic hypoxia, which is implicated in the progression of AD. Decreased oxygen supply disrupts neuronal energy homeostasis, induces oxidative stress, and compromises mitochondrial function (\nNeth and Craft, 2017\n). Under hypoxic conditions, cells activate adaptive responses mediated by hypoxia-inducible factor-1 (HIF-1), which regulates genes involved in angiogenesis, cell survival, and glucose metabolism. However, sustained HIF-1 activation in the context of neurodegeneration may exacerbate inflammation and promote A\u03b2 production, thereby worsening synaptic dysfunction and neuronal damage (\nZhang et al., 2007\n).", "doc_items_refs": ["#/texts/267", "#/texts/268", "#/texts/269", "#/texts/270", "#/texts/271", "#/texts/272", "#/texts/273", "#/texts/274", "#/texts/275", "#/texts/276", "#/texts/277", "#/texts/278", "#/texts/279"], "page_nos": [], "uuid": "923bded1-a712-48b8-a077-dfc64eb5b6d2"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 7, "source_chunk_idxs": [7], "num_tokens": 490, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\n2 Neuronal metabolism and Alzheimer's disease\nIn addition to impaired glucose metabolism, extensive clinical, preclinical, and epidemiological data have linked lipid metabolic dysfunction to AD risk. Lipids are essential for numerous brain processes, including synaptic regulation, myelin sheath formation, and energy storage. Given the brain's high lipid content, numerous studies have identified early alterations in specific lipid classes in AD, such as decreased plasmalogens, sulfatides, and elevated ceramides (\nHan, 2005\n). Lipids also modulate APP trafficking and processing, influencing neurotoxic A\u03b2 peptide formation (\nPenke et al., 2018\n).\nApolipoprotein E (APOE) is a key lipid-transporting protein primarily involved in cholesterol and phospholipid metabolism in both peripheral tissues and the central nervous system. It exists in three major isoforms in humans -APOE2, APOE3, and APOE4- which differ by single amino acid substitutions and exhibit distinct structural and functional properties. While APOE3 is the most prevalent and considered the \"neutral\" isoform, APOE2 is often associated with protective effects against neurodegeneration. In contrast, APOE4 has been consistently linked to increased risk and earlier onset of Alzheimer's disease (AD), possibly due to its detrimental influence on lipid homeostasis, mitochondrial integrity, and neuroinflammatory pathways (\nVolgman et al., 2024\n;\nGuo et al., 2025\n).\nApolipoprotein E4 (ApoE4) is a major genetic risk factor that connects lipid metabolism disorders with AD. Recent studies have highlighted lipid droplet accumulation in ApoE4 carriers, especially within phagocytic cells. In these microglia, lipid overload impairs phagocytosis and increases inflammatory responses, contributing to neurodegeneration. Lipid dyshomeostasis interacts with several AD pathogenic pathways, including amyloidogenesis, mitochondrial dysfunction, oxidative stress, neuroinflammation, and myelin degeneration (\nYin, 2023\n;\nJackson et al., 2024\n).", "doc_items_refs": ["#/texts/280", "#/texts/281", "#/texts/282", "#/texts/283", "#/texts/284", "#/texts/285", "#/texts/286", "#/texts/287", "#/texts/288", "#/texts/289", "#/texts/290", "#/texts/291", "#/texts/292", "#/texts/293", "#/texts/294"], "page_nos": [], "uuid": "2909aaeb-9fcf-4a75-bbf3-f7dbadbb8d2a"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 8, "source_chunk_idxs": [8], "num_tokens": 480, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\n2 Neuronal metabolism and Alzheimer's disease\nThe human APOE gene encodes the 34-kDa lipid-binding protein ApoE, which mediates lipid transport throughout peripheral organs and between brain cells (\nHauser et al., 2011\n). Compared to the common \u03b53 isoform, the \u03b54 variant is the strongest genetic risk factor for late-onset AD (\nHoulden et al., 1998\n), while the \u03b52 isoform significantly reduces risk (\nReiman et al., 2020\n). Each ApoE4 allele increases AD risk three- to fourfold and lowers the age of onset by approximately 8 years (\nNeu et al., 2017\n).\nApoE4 also exerts pathological effects by disrupting lipid concentration homeostasis. ApoE4 carriers exhibit higher plasma levels of total cholesterol and triglycerides, but reduced HDL cholesterol, while ApoE2 carriers show the opposite pattern (\nNotkola et al., 1998\n;\nHuang and Mahley, 2014\n). Additionally, ApoE4 enhances cytosolic phospholipase A2 (cPLA2) activity, increasing arachidonic acid production. ApoE4-associated pathology can be mitigated by DHA-rich (docosahexaenoic acid) diets but worsens with high-cholesterol intake (\nWang et al., 2005\n;\nGrimm et al., 2017\n).\nCholesterol, sphingolipids, and polyunsaturated fatty acids are particularly implicated in AD pathogenesis. Understanding lipid alterations may lead to therapeutic strategies targeting lipids, which could vary depending on disease stage, ApoE status, and metabolic profiles [28]. Other genes related to lipid metabolism and AD risk include TREM2, APOJ, PICALM, ABCA1, and ABCA7, all involved in lipid transport. Additionally, SREBP-2, a key regulator of cholesterol metabolism, has also been genetically associated with increased AD risk (\nZhao et al., 2015\n;\nKober and Brett, 2017\n;\nShimano and Sato, 2017\n;\nYin, 2023\n).", "doc_items_refs": ["#/texts/295", "#/texts/296", "#/texts/297", "#/texts/298", "#/texts/299", "#/texts/300", "#/texts/301", "#/texts/302", "#/texts/303", "#/texts/304", "#/texts/305", "#/texts/306", "#/texts/307", "#/texts/308", "#/texts/309", "#/texts/310", "#/texts/311", "#/texts/312", "#/texts/313", "#/texts/314", "#/texts/315", "#/texts/316", "#/texts/317", "#/texts/318", "#/texts/319", "#/texts/320", "#/texts/321"], "page_nos": [], "uuid": "f6e468aa-d6a8-46d6-934b-99f68c1b0f50"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 9, "source_chunk_idxs": [9], "num_tokens": 377, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\n3 The mitochondrial theory of Alzheimer's disease\nMitochondria possess their own genome, which enables the synthesis of proteins essential for their function. This genome encodes 13 subunits of the complexes that constitute the electron transport chain (ETC), while the remaining subunits, along with other mitochondrial proteins, are encoded by nuclear DNA. Due to the absence of histones, mitochondrial DNA (mtDNA) is particularly vulnerable to oxidative stress. Moreover, its limited capacity for repair and recombination increases the accumulation of mutations that compromise mitochondrial function (\nElson et al., 2006\n). Structural alterations in mtDNA are exacerbated in patients with AD, with microscopic analyses revealing abnormally small mitochondria and disrupted cristae, particularly in the mammillary bodies and certain hypothalamic regions (\nBaloyannis et al., 2015\n;\nBaloyannis et al., 2016\n). Several studies have also reported a higher incidence of oxidized nucleotides and an increased number of mutations in the coding regions of mtDNA in AD patients (\nWang et al., 2005\n).\nAlthough little is known about the epigenetic regulation of mtDNA, significant differences in mtDNA methylation have been observed between individuals with AD and healthy controls (\nStoccoro et al., 2017\n). Mitochondrial function depends on a dynamic equilibrium between fusion and fission. Mitochondrial fusion allows the merging of individual organelles, promoting the exchange of materials and dilution of damaged components, thus maintaining mitochondrial efficiency. In contrast, fission generates smaller mitochondria, facilitating the selective removal of dysfunctional organelles through mitophagy and ensuring proper mitochondrial distribution according to cellular energy demands.", "doc_items_refs": ["#/texts/323", "#/texts/324", "#/texts/325", "#/texts/326", "#/texts/327", "#/texts/328", "#/texts/329", "#/texts/330", "#/texts/331", "#/texts/332", "#/texts/333", "#/texts/334"], "page_nos": [], "uuid": "5c6e3e41-ca24-4861-9ed2-e8e9a62ce553"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 10, "source_chunk_idxs": [10], "num_tokens": 488, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\n3 The mitochondrial theory of Alzheimer's disease\nIn AD, increased mitochondrial fission leads to excessive fragmentation. Postmortem studies have shown elevated expression of mitochondrial fission proteins in the prefrontal cortex of AD patients (\nManczak et al., 2011\n). Several experimental studies have demonstrated that mitochondrial dysfunction is an early and central feature in the pathogenesis AD. In rodent models, intracerebroventricular (icv) administration of streptozotocin (STZ) has been widely used to mimic sporadic AD by inducing brain insulin resistance, oxidative stress, and cognitive decline, without affecting peripheral glycemic control. Unlike systemic administration, which causes selective pancreatic \u03b2-cell destruction via GLUT2 transporters and is used to model type 1 diabetes mellitus (T1DM), icv-STZ acts directly on neurons in the central nervous system (CNS). Notably, STZ-treated animals exhibit alterations in mitochondrial dynamics, including increased expression of fission proteins such as Drp1 and Fis1, accompanied by decreased levels of fusion-related proteins like Mfn2 and OPA1, particularly in the hippocampus and in the prefrontal cortex (\nPaidi et al., 2015\n;\nJoshi et al., 2018\n). Transgenic AD models such as APP/PS1 mice, which overexpress mutant human amyloid precursor protein and presenilin-1, have also revealed mitochondrial fragmentation and respiratory deficits, reinforcing the hypothesis that impaired mitochondrial dynamics and mitophagy are mechanistically linked to AD pathology. These findings suggest that mitochondrial fragmentation and bioenergetic failure contribute to neurodegeneration and cognitive impairment in this model.\nGiven that mitochondrial bioenergetic alterations appear early in the disease course, they are considered potential primary events underlying synaptic failure, neuroinflammation, oxidative stress, and neuronal loss (\nJoshi et al., 2018\n). Mitochondria are central to ATP production via oxidative phosphorylation and regulate calcium homeostasis, cell growth, and metabolism (\nDu et al., 2010\n;\nPeggion et al., 2024\n).", "doc_items_refs": ["#/texts/335", "#/texts/336", "#/texts/337", "#/texts/338", "#/texts/339", "#/texts/340", "#/texts/341", "#/texts/342", "#/texts/343", "#/texts/344", "#/texts/345", "#/texts/346", "#/texts/347", "#/texts/348"], "page_nos": [], "uuid": "c5bdb2cc-95bc-4ff5-b7ec-f2ac5e29158f"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 11, "source_chunk_idxs": [11], "num_tokens": 454, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\n3 The mitochondrial theory of Alzheimer's disease\nOne hallmark of AD is the impaired removal of damaged mitochondria due to defective autophagy. A particular alteration involves lysosomal dysfunction, which hinders the degradation of structurally damaged mitochondria, leading to cellular toxicity (\nMcGill Percy et al., 2025\n). Furthermore, mitochondrial impairment can, in turn, disrupt endolysosomal processes, as endolysosomal biogenesis may be modulated in response to mitochondrial damage (\nFernandez-Mosquera et al., 2017\n). Studies have shown that mitochondrial dysfunction alters lysosomal function and morphology, either through exposure to mitochondrial toxins or deletion of proteins such as apoptosis-inducing factor (AIF), PTEN-induced kinase 1 (PINK1), or the ubiquitin ligase Parkin (\nDemers-Lamarche et al., 2016\n).\nIn AD, dysfunctional mitochondria accumulate and exacerbate lysosomal degradation bottlenecks. Affected neurons exhibit mitochondrial membrane potential loss, resulting in microtubule network disintegration and impaired autophagic flux toward lysosomes (\nSilva et al., 2017\n;\nBrewer et al., 2020\n). A\u03b2-induced oxidative stress further disrupts mitochondrial mobility and function (\nBrewer et al., 2020\n), establishing a negative feedback loop wherein A\u03b2 exacerbates mitochondrial dysfunction, which in turn promotes further A\u03b2 accumulation.\nMitochondrial dysfunction also contributes to tau pathology by increasing \u03c4 oligomer levels and shifting the monomer-oligomer balance toward toxic oligomers (\nWeidling et al., 2020\n). During oxidative phosphorylation, mitochondria generate and scavenge reactive oxygen species (ROS). However, persistent ROS overproduction exceeding antioxidant capacity leads to damage of cellular macromolecules, including phospholipids, proteins, and nucleic acids, compromising cellular function (\nLane C. A. et al., 2018\n).", "doc_items_refs": ["#/texts/349", "#/texts/350", "#/texts/351", "#/texts/352", "#/texts/353", "#/texts/354", "#/texts/355", "#/texts/356", "#/texts/357", "#/texts/358", "#/texts/359", "#/texts/360", "#/texts/361", "#/texts/362", "#/texts/363", "#/texts/364", "#/texts/365", "#/texts/366", "#/texts/367"], "page_nos": [], "uuid": "b1b3f863-8593-4e26-baae-b7fab5b66990"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 12, "source_chunk_idxs": [12], "num_tokens": 151, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\n3 The mitochondrial theory of Alzheimer's disease\nElevated ROS levels can also result from A\u03b2 modifications; for instance, the Met35 residue of A\u03b2, along with upregulated oxidases such as NADPH oxidases and monoamine oxidase B (MAO-B), increase ROS production. Moreover, A\u03b2 interactions with excess metals-such as Fe\n2+\n, Cu\n2+\n, and Zn\n2+\n-further elevate oxidative stress (\nLane D. J. R. et al., 2018\n;\nBai et al., 2022\n).", "doc_items_refs": ["#/texts/368", "#/texts/369", "#/texts/370", "#/texts/371", "#/texts/372", "#/texts/373", "#/texts/374", "#/texts/375", "#/texts/376", "#/texts/377", "#/texts/378"], "page_nos": [], "uuid": "6a06750c-5027-41aa-a62a-dc248f80f5e0"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 13, "source_chunk_idxs": [13], "num_tokens": 464, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\n4 Role of estrogens in neuronal function\nEstrogens are steroid hormones primarily produced in the ovaries of women of reproductive age. Their primary biological activity is mediated by receptors belonging to the nuclear receptor superfamily, which function as transcription factors that modulate gene expression. After crossing the plasma membrane-facilitated by their steroid structure-estrogens bind to cytoplasmic receptors, which translocate to the nucleus and interact with DNA to regulate transcription (\nLonard and O'Malley, 2006\n).\nEstrogen receptors exist in two main isoforms, ER\u03b1 and ER\u03b2, both widely distributed throughout the body (\nMatthews and Gustafsson, 2003\n). These receptors form dimers and bind to specific DNA sequences known as estrogen response elements (EREs) in the promoter regions of target genes. Notably, approximately one-third of estrogen-regulated genes lack canonical EREs, suggesting alternative regulatory mechanisms (\nJohri et al., 2024\n;\nPeralta and Lizcano, 2024\n). Molecular and biochemical studies have shown that estrogens may also exert transcriptional effects via protein-protein interactions with other transcription factors (\nAranda and Pascual, 2001\n;\nMarino et al., 2006\n;\nMauvais-Jarvis et al., 2013\n).\nMany estrogenic effects are not genomic and occur more rapidly than expected from transcriptional activation. The discovery of the G-protein-coupled estrogen receptor (GPER1) in the early 2000s provided insight into these non-genomic mechanisms (\nNilsson et al., 2011\n). GPER1 mediates rapid signaling cascades involving adenylate cyclase, cyclic AMP, protein kinase A, and other second messengers. GPER1 mRNA and protein have been detected in blood vessels and cardiac tissue across various species (\nHaas et al., 2009\n). Expression in adipocytes, hepatocytes, and myocytes is more variable, and the precise\nin vivo\nrole of GPER1 remains under debate (\nMeyer et al., 2011\n;\nHewitt et al., 2017\n;\nLuo and Liu, 2020\n).", "doc_items_refs": ["#/texts/380", "#/texts/381", "#/texts/382", "#/texts/383", "#/texts/384", "#/texts/385", "#/texts/386", "#/texts/387", "#/texts/388", "#/texts/389", "#/texts/390", "#/texts/391", "#/texts/392", "#/texts/393", "#/texts/394", "#/texts/395", "#/texts/396", "#/texts/397", "#/texts/398", "#/texts/399", "#/texts/400", "#/texts/401", "#/texts/402", "#/texts/403", "#/texts/404", "#/texts/405", "#/texts/406", "#/texts/407", "#/texts/408"], "page_nos": [], "uuid": "2abcd5ef-a505-466c-85d1-e3b0d3b1dd2c"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 14, "source_chunk_idxs": [14], "num_tokens": 472, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\n4 Role of estrogens in neuronal function\nLigand-independent actions of estrogen receptors (ERs) have also been described, particularly in the uterus, where ER\u03b1 can be activated by growth factor pathways (e.g., IGF-1), leading to receptor recruitment to chromatin in the absence of estrogen binding (\nMeyer et al., 2011\n;\nHewitt et al., 2017\n) (see\nFigure 1\n).\nFigure 1\nFigure 1\n. Estrogen signaling mechanisms.\n(A)\nGenomic signaling: Estrogens cross the plasma membrane and bind to the cytoplasm's estrogen receptors (ERs). The estrogen-ER complex moves into the nucleus, forming homodimer and/or heterodimer complexes. These complexes bind to specific estrogen-sensitive elements (EREs) in DNA or recruit transcription factors.\n(B)\nNon-genomic signaling: Estrogens can perform a non-genomic effect by binding to their receptors on the plasma membrane. Additionally, some ERb are in the plasma membrane that induce the signaling cascade. Non-genomic information is established by extracellular signaling that stimulates second messengers in the cytoplasm; Responses are mediated by specific G-protein-coupled (GPER) receptors or estrogen receptors on the membrane. Finally, non-genomic action can indirectly increase gene expression.\nEstrogens play a multifaceted role in the central nervous system (CNS), influencing synaptic plasticity, neuronal development, and survival in newly formed spinal synapses, as well as promoting neural stem cell proliferation and maintaining the integrity of the blood-brain barrier (\nMcCullough et al., 2003\n;\nMukai et al., 2010\n;\nFrick et al., 2015\n;\nNa et al., 2015\n). Both neuron- and astrocyte-derived estrogens are believed to contribute significantly to neuroprotection and cognitive function through interactions with ERs expressed in multiple brain regions (\nMcEwen and Woolley, 1994\n;\nMcEwen et al., 1995\n;\nAzcoitia et al., 2001\n).", "doc_items_refs": ["#/texts/409", "#/texts/410", "#/texts/411", "#/texts/412", "#/texts/413", "#/texts/414", "#/texts/415", "#/texts/416", "#/texts/417", "#/texts/418", "#/texts/419", "#/texts/420", "#/texts/421", "#/texts/422", "#/texts/423", "#/texts/424", "#/texts/425", "#/texts/426", "#/texts/427", "#/texts/428", "#/texts/429", "#/texts/430", "#/texts/431", "#/texts/432", "#/texts/433", "#/texts/434", "#/texts/435", "#/texts/436", "#/texts/437"], "page_nos": [], "uuid": "1715fc00-08f3-4bd1-8c08-c8f6b4f4d3c8"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 15, "source_chunk_idxs": [15], "num_tokens": 238, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\n4 Role of estrogens in neuronal function\nPreclinical and human studies have shown that ER\u03b1 is abundantly expressed in the hypothalamus, particularly in the preoptic area (POA), ventromedial nuclei (VMN), amygdala, and periventricular nuclei (PV). ER\u03b2 exhibits a similar distribution, maintaining high expression in the POA, bed nucleus of the stria terminalis (BNST), PV, and supraoptic nuclei (\nLaflamme et al., 1998\n;\nAzcoitia et al., 2001\n;\nKruijver et al., 2003\n;\nMitra et al., 2003\n;\nKelly and Ronnekleiv, 2012\n). ER\u03b2 is also expressed in the hippocampus, amygdala, and cerebral cortex, where it participates in adult neurogenesis, synaptic plasticity, and new neuron formation (\nWeiser et al., 2008\n).", "doc_items_refs": ["#/texts/438", "#/texts/439", "#/texts/440", "#/texts/441", "#/texts/442", "#/texts/443", "#/texts/444", "#/texts/445", "#/texts/446", "#/texts/447", "#/texts/448", "#/texts/449", "#/texts/450"], "page_nos": [], "uuid": "22371645-8e3e-470c-9e57-63ff1371d706"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 16, "source_chunk_idxs": [16], "num_tokens": 396, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\n4 Role of estrogens in neuronal function\nPostnatal expression of ER\u03b2 tends to decline, but it remains present in microglia, oligodendrocytes, and specific brain regions, such as the hypothalamus and amygdala (\nVargas et al., 2016\n). ER\u03b2 signaling has been associated with several potential therapeutic benefits in CNS disorders: (1) it enhances GABAergic over glutamatergic signaling, exerting anticonvulsant effects (\nVeliskova and Desantis, 2013\n); (2) promotes oligodendrocyte maturation and myelination (\nVargas et al., 2016\n;\nKarim et al., 2018\n); (3) modulates microglial activation and reduces inflammation (\nValdes-Sustaita et al., 2021\n); and (4) supports serotonergic neurons, providing antidepressant effects (\nSuzuki et al., 2006\n). In both rodent models and postmenopausal women, ER\u03b2 ligands have shown beneficial effects on anxiety, depression, epilepsy, and multiple sclerosis (\nWarner and Gustafsson, 2015\n;\nJellinger, 2024\n). However, clinical outcomes in humans have been inconsistent, potentially due to alternative splicing variants of ER\u03b2, which may alter therapeutic responsiveness (\nKim et al., 2018\n;\nUlhaq and Garcia, 2021\n). Some natural compounds with estrogenic effects, such as polyphenols, have a beneficial impact on neurons by mitigating oxidative stress, inflammation, and apoptosis. However, their direct effects on the progression of Alzheimer's disease have not been established (\nAbdelsalam et al., 2023\n).", "doc_items_refs": ["#/texts/451", "#/texts/452", "#/texts/453", "#/texts/454", "#/texts/455", "#/texts/456", "#/texts/457", "#/texts/458", "#/texts/459", "#/texts/460", "#/texts/461", "#/texts/462", "#/texts/463", "#/texts/464", "#/texts/465", "#/texts/466", "#/texts/467", "#/texts/468", "#/texts/469", "#/texts/470", "#/texts/471", "#/texts/472", "#/texts/473"], "page_nos": [], "uuid": "2a9c546e-60be-450f-813d-e4a83ca9efd9"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 17, "source_chunk_idxs": [17], "num_tokens": 227, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\n4 Role of estrogens in neuronal function\nEstrogens can also be synthesized\nde novo\nin the brain by neurons and astrocytes, starting from cholesterol (\nBlakemore and Naftolin, 2016\n). Moreover, local steroid metabolism in the brain can produce estrogens via aromatase, the enzyme responsible for converting androgens into estrogens (\nGillies and McArthur, 2010\n;\nBrann et al., 2022\n). Aromatase expression varies across brain regions, with high levels found in the cerebellum, amygdala, hippocampus, and white matter. While sex differences in expression are not apparent in these regions, elevated aromatase levels have been reported in the hypothalamus-specifically in the POA and VMN-of male animals, suggesting regulation by circulating testosterone, which is subsequently converted to estradiol (E2) (\nGillies and McArthur, 2010\n).", "doc_items_refs": ["#/texts/474", "#/texts/475", "#/texts/476", "#/texts/477", "#/texts/478", "#/texts/479", "#/texts/480", "#/texts/481", "#/texts/482", "#/texts/483", "#/texts/484"], "page_nos": [], "uuid": "06a72d79-921b-4e84-93bf-960e68339287"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 18, "source_chunk_idxs": [18], "num_tokens": 439, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\n5 Estrogen effects on mitochondrial function\nIt is also important to consider the impact of estrogens on mitochondrial function. Mitochondria play a critical role in regulating cell survival and apoptosis, and the respiratory chain is a principal structural and functional target of estrogenic activity. Estrogens exert protective effects against oxidative stress by promoting the translocation of specific cytosolic enzymes into mitochondria, thereby shielding mitochondrial DNA (mtDNA) from free radical-induced damage (\nLeclere et al., 2013\n;\nArjmand et al., 2024\n).\nThe distribution of ER\u03b1 and ER\u03b2 in patients with AD varies considerably across brain regions. In women with AD, increased ER\u03b1 expression has been observed in certain hippocampal areas, whereas levels are lower in hypothalamic nuclei and the medial mammillary nucleus (\nHestiantoro and Swaab, 2004\n). However, overall, ER\u03b1 has not been consistently implicated in AD pathogenesis. In contrast, growing evidence supports a protective role for ER\u03b2, which appears to influence both disease risk and progression. In animal models, ER\u03b2 overexpression has been associated with reduced A\u03b2 plaque deposition. Human studies have reported decreased ER\u03b2 levels in the frontal cortex of women with AD (\nLong et al., 2012\n;\nTian et al., 2013\n).\nThe presence of estrogen receptors within mitochondria was initially identified in MCF-7 breast cancer cell lines and later confirmed in brain cells. Estrogens may influence mitochondrial function through both direct and indirect mechanisms. Specifically, ER\u03b2 upregulates nuclear respiratory factor 1 (NRF-1), which in turn stimulates the expression of mitochondrial biogenesis regulators, including mitochondrial transcription factor A (TFAM), and multiple subunits of the mitochondrial respiratory chain (MRC). These factors contribute to the regulation of mitochondrial gene expression and the maintenance of mitochondrial homeostasis (see\nFigure 2\n).\nFigure 2", "doc_items_refs": ["#/texts/486", "#/texts/487", "#/texts/488", "#/texts/489", "#/texts/490", "#/texts/491", "#/texts/492", "#/texts/493", "#/texts/494", "#/texts/495", "#/texts/496", "#/texts/497", "#/texts/498", "#/texts/499", "#/texts/500", "#/texts/501"], "page_nos": [], "uuid": "a8035926-521e-4d62-8019-3d4c4b8631cd"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 19, "source_chunk_idxs": [19], "num_tokens": 328, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\n5 Estrogen effects on mitochondrial function\nFigure 2\n. Los estr\u00f3genos pueden inducir la expresi\u00f3n de genes que aumentan la funci\u00f3n mitocondrial, como SIRT3, PGC-1\u03b1, NRF1. ER\u03b2 increases NRF-1 which, in turn, increases TFAM that stimulates mtDNA transcription. Estradiol can increase glucose utilization by cells and ETC activity and prevent ROS production. E2 regulate many enzymes in the TCA. E2, estradiol; mtDNA, mitochondrial DNA; SIRT3, Sirtuin 3; PGC-1\u03b1, Peroxisome proliferator-activated receptor gamma, coactivator-1 alpha; NRF1, Nuclear respiratory factor \u22121; ER\u03b2, Estrogen receptor beta; TFAM, Transcription factor A, mitochondrial; TCA, tricarboxylic acid cycle; ETC, Electron transport chain.\nA decline in estradiol (E2) levels leads to significant reductions in mitochondrial function, resulting in oxidative stress and impaired cerebral bioenergetics. Preclinical studies have shown increased hippocampal A\u03b2 accumulation under E2-deficient conditions. This phenotype is characterized by reduced maximal respiratory capacity, diminished basal oxygen consumption, and lower extracellular acidification rates-indicative of decreased lactate production and glycolytic activity (\nIrwin et al., 2012\n).", "doc_items_refs": ["#/texts/502", "#/texts/503", "#/texts/504", "#/texts/505", "#/texts/506"], "page_nos": [], "uuid": "d181e3d0-b94b-41d6-8958-b1c66585f337"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 20, "source_chunk_idxs": [20], "num_tokens": 261, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\n5 Estrogen effects on mitochondrial function\nEstrogens regulate the expression and activity of key enzymes in glycolysis, including hexokinase, phosphoglucoisomerase, phosphofructokinase, aldolase, glyceraldehyde-3-phosphate dehydrogenase, phosphoglycerate kinase, 6-phosphofructo-2-kinase, and fructose 2,6-bisphosphatase (\nLizcano and Guzman, 2014\n). Estrogens also enhance the expression of glucose transporters GLUT3 and GLUT4 in the brain (\nStirone et al., 2005\n;\nRazmara et al., 2008\n). In addition, estrogenic regulation extends to enzymes of the tricarboxylic acid (TCA) cycle, such as citrate synthase, mitochondrial aconitase 2, isocitrate dehydrogenase, and succinate dehydrogenase (\nNilsen et al., 2007\n;\nAlaynick, 2008\n;\nLizcano, 2022\n).", "doc_items_refs": ["#/texts/507", "#/texts/508", "#/texts/509", "#/texts/510", "#/texts/511", "#/texts/512", "#/texts/513", "#/texts/514", "#/texts/515", "#/texts/516", "#/texts/517", "#/texts/518", "#/texts/519"], "page_nos": [], "uuid": "9f5348e0-22d2-4ef1-b703-66153041f2aa"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 21, "source_chunk_idxs": [21], "num_tokens": 389, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\n6 Do GLP-1 receptor agonists influence mitochondria and Alzheimer's disease?\nType 2 diabetes mellitus (T2DM) and AD share metabolic abnormalities, including insulin resistance, mitochondrial dysfunction, inflammation, and increased oxidative stress. Incretin-based antidiabetic therapies, such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), may offer benefits for individuals at risk of neurodegeneration due to their central effects on appetite and satiety regulation via the hypothalamus (\nCorreia et al., 2012\n). Beyond glucose lowering and weight reduction, GLP-1RAs have shown positive effects on cognitive dysfunction in T2DM patients (\nReich and Holscher, 2022\n).\nWhile GLP-1 is primarily synthesized and secreted by intestinal L-cells in response to nutrient intake, it is also produced in the brain, particularly in the nucleus of the solitary tract in the brainstem. Following the ingestion of carbohydrates and fats, GLP-1 is released and exerts multiple physiological effects essential for maintaining glucose homeostasis (\nBullock et al., 1996\n). It promotes glucose-dependent insulin secretion from pancreatic \u03b2-cells, ensuring proportional release relative to glycemia, and concurrently inhibits glucagon secretion from \u03b1-cells, reducing hepatic glucose production. GLP-1 also delays gastric emptying, thereby moderating postprandial glycemic excursions, and enhances satiety via central nervous system (CNS) signaling, contributing to appetite suppression and weight loss (\nDrucker, 2006\n).", "doc_items_refs": ["#/texts/521", "#/texts/522", "#/texts/523", "#/texts/524", "#/texts/525", "#/texts/526", "#/texts/527", "#/texts/528", "#/texts/529", "#/texts/530"], "page_nos": [], "uuid": "b1ac3348-8e06-4250-9e6d-2211e1af10a0"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 22, "source_chunk_idxs": [22], "num_tokens": 494, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\n6 Do GLP-1 receptor agonists influence mitochondria and Alzheimer's disease?\nMetabolically, GLP-1 acts through G protein-coupled receptors to improve insulin sensitivity in muscle and adipose tissues while enhancing \u03b2-cell function by promoting proliferation and inhibiting apoptosis (see\nFigure 3\n). Additionally, GLP-1RAs exert cardiovascular benefits, including improved endothelial function, reduced blood pressure, and cardioprotection. Clinically, GLP-1RAs-such as exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide-are used to manage T2DM, mimicking endogenous GLP-1 activity. These agents not only enhance glycemic control but also promote satiety and delay gastric emptying, making them effective in treating obesity (\nDrucker et al., 1987\n;\nKreymann et al., 1987\n;\nMojsov et al., 1987\n;\nTurton et al., 1996\n;\nBaggio and Drucker, 2007\n). The effects of GLP-1 on different tissues have demonstrated an enhanced insulin effect on skeletal muscle through SESN2-mediated autophagy and the attenuation of IRS1 serine phosphorylation (\nTian et al., 2023\n). In obese mouse models, liraglutide improved insulin sensitivity in visceral adipose tissue, which was associated with reduced endoplasmic reticulum stress and increased Akt phosphorylation following insulin stimulation (\nJiang et al., 2018\n). However, regarding the proliferation of insulin-producing pancreatic beta cells, there is no consensus regarding the ability to stimulate cell proliferation. Although GLP-1 receptor agonists have been shown to induce \u03b2-cell proliferation in rodent models, particularly in young animals, this effect has not been consistently replicated in human islets, where \u03b2-cell replication capacity is markedly limited. Thus, in humans, GLP-1 action appears to be predominantly functional and anti-apoptotic rather than proliferative (\nDai et al., 2017\n;\nButeau et al., 2003\n).\nFigure 3", "doc_items_refs": ["#/texts/531", "#/texts/532", "#/texts/533", "#/texts/534", "#/texts/535", "#/texts/536", "#/texts/537", "#/texts/538", "#/texts/539", "#/texts/540", "#/texts/541", "#/texts/542", "#/texts/543", "#/texts/544", "#/texts/545", "#/texts/546", "#/texts/547", "#/texts/548", "#/texts/549", "#/texts/550", "#/texts/551", "#/texts/552"], "page_nos": [], "uuid": "565cb2ea-7ecf-4693-814d-2f4f570cc99c"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 23, "source_chunk_idxs": [23], "num_tokens": 380, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\n6 Do GLP-1 receptor agonists influence mitochondria and Alzheimer's disease?\nFigure 3\n. GLP-1RA activation initiates a cascade of signaling events through G\n\u03b1s\ncoupling, leading to the activation of adenylyl cyclase (AC) and subsequent production of cAMP. Protein kinase A (PKA) acts as a central mediator of downstream effects, modulating various ion channels. These channels jointly regulate membrane depolarization and calcium (Ca\n2+\n) influx. Parallel signaling through Akt activates ERK 1/2, which differentiates cellular responses: nuclear translocation of ERK 1/2 leads to transcriptional activation via mTOR and CREB, while cytoplasmic activation targets specific partners. The PI3K/AKT pathway regulates cell survival and metabolism. Calcium-dependent activation of CaMKII modulates these processes, emphasizing the complexity and versatility of GLP-1R signaling. Activation of PKA increase Memory, BDNF reduce oxidative stress and synapse loss. GSK-3\u03b2 reduce tau phosphorylation, Akt reduce cytotoxity and apoptosis. PI3K, phosphoinositide 3-kinase; PKA, Protein kinase A; AkT, protein kinase B; ERK, Extracellular Signal-regulated Kinase; mTOR, mammalian target of rapamycin; GSK-3\u03b2, glycogen synthase kinase-3\u03b2; CREB, cAMP response element-binding protein; BDNF, Brain-derived neurotrophic factor; CaMKII, Ca2+/calmodulin-dependent protein kinase II.", "doc_items_refs": ["#/texts/553", "#/texts/554", "#/texts/555", "#/texts/556", "#/texts/557", "#/texts/558"], "page_nos": [], "uuid": "a7d5963c-ba8b-4bdd-bdeb-a464edba0542"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 24, "source_chunk_idxs": [24], "num_tokens": 436, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\n6 Do GLP-1 receptor agonists influence mitochondria and Alzheimer's disease?\nBoth peripherally secreted GLP-1 and pharmacologic GLP-1RAs can cross the blood-brain barrier (BBB) or interact with circumventricular organs, suggesting that peripheral administration is sufficient to reach CNS targets. Central administration of GLP-1RAs reduces food intake, likely via GLP-1 receptor-expressing regions in the hypothalamus and brainstem (\nKastin and Akerstrom, 2003\n), many of which are also estrogen targets (\nKanoski et al., 2011\n), supporting a potential interaction between these systems (\nMiller, 2012\n). Substantial evidence suggests that GLP-1R signaling in the central nervous system (CNS) modulates reward-driven behavior, including food cravings and substance addiction, underscoring the broader implications of these peptides in neurobehavioral regulation (\nShirazi et al., 2013\n;\nRichard et al., 2015\n).\nRecent investigations have explored the therapeutic potential of GLP-1 in cardiovascular disease, metabolic-associated fatty liver disease, Parkinson's disease, and AD. These multifaceted mechanisms underscore the relevance of GLP-1 in managing metabolic, cardiovascular, and neurodegenerative disorders (\nCukierman-Yaffe et al., 2020\n;\nArredouani, 2025\n).\nThe cloning and characterization of the GLP-1 receptor (GLP-1R) marked a key milestone in understanding GLP-1's mechanisms of action. Pharmacological and molecular biology studies identified GLP-1R as a high-affinity receptor expressed across diverse tissues. As a member of the G protein-coupled receptor (GPCR) family, GLP-1R features a large extracellular domain responsible for ligand recognition and binding (\nDrucker and Holst, 2023\n).", "doc_items_refs": ["#/texts/559", "#/texts/560", "#/texts/561", "#/texts/562", "#/texts/563", "#/texts/564", "#/texts/565", "#/texts/566", "#/texts/567", "#/texts/568", "#/texts/569", "#/texts/570", "#/texts/571", "#/texts/572", "#/texts/573", "#/texts/574", "#/texts/575", "#/texts/576", "#/texts/577"], "page_nos": [], "uuid": "98ef3674-41f9-4be3-81ac-0f162047954e"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 25, "source_chunk_idxs": [25], "num_tokens": 494, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\n6 Do GLP-1 receptor agonists influence mitochondria and Alzheimer's disease?\nThe widespread expression of GLP-1R suggests that GLP-1 plays pleiotropic physiological roles beyond insulin secretion. In the CNS, GLP-1 has demonstrated neuroprotective effects, particularly in the hippocampus and cerebral cortex-key regions for memory and learning. These benefits include reducing neuroinflammation, improving neuronal energy homeostasis, and limiting neurodegenerative progression (\nAdams et al., 2018\n;\nChang et al., 2018\n).\nPotential mechanisms by which GLP-1RAs enhance cognition in T2DM patients include attenuation of oxidative stress, suppression of neuroinflammation, inhibition of apoptosis, reduction or prevention of A\u03b2 accumulation, and mitigation of tau aggregation (\nYaribeygi et al., 2021\n). Several preclinical studies have confirmed the ability of GLP-1RAs to reduce A\u03b2 and tau deposits. Although findings in human studies have been less consistent, a pilot study reported reduced cerebrospinal fluid levels of A\u03b242, and a large-scale clinical trial is currently underway to assess the efficacy of a GLP-1RA in early-stage AD patients (\nCrook and Edison, 2024\n;\nCummings et al., 2025\n).\nThese pharmacological advances have reshaped the management of metabolic diseases, improving glycemic control, weight reduction, and cardiovascular outcomes. As research continues, GLP-1's therapeutic potential in AD remains a promising frontier (\nGejl et al., 2016\n;\nDu et al., 2022\n). Phase II clinical trial results with liraglutide support this hypothesis. In a multicenter UK study involving 204 participants randomized to liraglutide or placebo, cognitive decline in the liraglutide group was 18% slower than in the placebo group after 1 year of treatment (\nFemminella et al., 2019\n). Liraglutide may reduce neuroinflammation, decrease insulin resistance, improve neuronal communication, and limit A\u03b2 and tau pathology.", "doc_items_refs": ["#/texts/578", "#/texts/579", "#/texts/580", "#/texts/581", "#/texts/582", "#/texts/583", "#/texts/584", "#/texts/585", "#/texts/586", "#/texts/587", "#/texts/588", "#/texts/589", "#/texts/590", "#/texts/591", "#/texts/592", "#/texts/593", "#/texts/594", "#/texts/595", "#/texts/596"], "page_nos": [], "uuid": "3eb9ddc2-5de1-4c25-a646-871bbab887b7"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 26, "source_chunk_idxs": [26], "num_tokens": 152, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\n6 Do GLP-1 receptor agonists influence mitochondria and Alzheimer's disease?\nCurrently, the first randomized, double-blind phase III trial is underway to evaluate the effects of oral Semaglutide in AD prevention and progression. The EVOKE and EVOKE + trials are supported by robust preclinical evidence demonstrating GLP-1RA benefits in neurodegeneration and cognitive enhancement in T2DM patients (\nAkimoto et al., 2020\n;\nCukierman-Yaffe et al., 2020\n;\nNorgaard et al., 2022\n).", "doc_items_refs": ["#/texts/597", "#/texts/598", "#/texts/599", "#/texts/600", "#/texts/601", "#/texts/602", "#/texts/603"], "page_nos": [], "uuid": "509454bf-ff62-4315-a093-e17e8eb5708b"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 27, "source_chunk_idxs": [27], "num_tokens": 448, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\n7 Could dual agonism of estrogen and GLP-1 influence Alzheimer's disease prevention?\nThe social and clinical impact of GLP-1RA therapy is reflected in the growing number of individuals using these medications. Currently, one in eight U.S. adults over the age of 18 reports having used a GLP-1 analogue (\nHarris, 2024\n). Additionally, novel combination therapies-such as Tirzepatide, which combines a GLP-1 analogue with glucose-dependent insulinotropic polypeptide (GIP)-are rapidly gaining traction, and it is expected that new formulations will continue to emerge, incorporating peptides capable of modulating metabolism and thermogenesis (\nJastreboff et al., 2022\n;\nRosenstock et al., 2023\n;\nLoomba et al., 2024\n).\nDespite their widespread use, certain aspects of GLP-1 function, particularly its actions in the central nervous system (CNS), remain poorly understood-an important gap given the growing number of patients receiving these treatments. A key limitation of preclinical research, including GLP-1RA studies, is that most experiments are conducted in male animals. This introduces variability in pharmacodynamics, as GLP-1RA penetration into specific brain regions may differ based on sex, compound properties, and age (\nBorchers and Skibicka, 2025\n).\nThis raises important questions for ongoing trials such as EVOKE, which may uncover sex-specific differences and justify subsequent investigations of GLP-1 analogues in female populations. Moreover, the combined effect of GLP-1RAs with other molecules may vary depending on sex. Known polymorphisms and splice variants in ER\u03b2 could influence the efficacy of estrogen therapy in AD and may also impact GLP-1RA activity. Exploring these potential interactions could enhance our understanding of brain-targeted pharmacotherapy (\nHolscher, 2018\n;\nJastreboff et al., 2022\n).", "doc_items_refs": ["#/texts/605", "#/texts/606", "#/texts/607", "#/texts/608", "#/texts/609", "#/texts/610", "#/texts/611", "#/texts/612", "#/texts/613", "#/texts/614", "#/texts/615", "#/texts/616", "#/texts/617", "#/texts/618", "#/texts/619", "#/texts/620", "#/texts/621"], "page_nos": [], "uuid": "1660903c-f2a3-4021-9c07-f10cf3879f01"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 28, "source_chunk_idxs": [28], "num_tokens": 457, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\n7 Could dual agonism of estrogen and GLP-1 influence Alzheimer's disease prevention?\nSex differences in the incidence and progression of aging-related neurodegenerative diseases, particularly Alzheimer's disease, are well established and globally consistent. In the United States, although men have higher age-adjusted mortality rates for 8 of the 10 leading causes of death, AD is a notable exception: women experience higher prevalence and AD-specific mortality, making it the only major cause of death more common in women (\nBudreviciute et al., 2020\n). This trend extends beyond the U.S., with higher AD burden reported among women in Europe, the United Kingdom, Japan, and other regions (\nBenziger et al., 2016\n).\nToday, nearly two-thirds of patients receiving medical care for AD are women. This statistic reflects both a higher age-adjusted incidence of AD and longer life expectancy among women (\nReport, 2024\n). However, this female predominance appears paradoxical given the greater prevalence of classical AD risk factors-such as cardiovascular and metabolic diseases-among men. One explanation involves survival bias: men with high AD risk may die earlier from cardiovascular events, precluding the clinical manifestation of dementia. Sociocultural factors, such as unequal access to education in the 20th century (a known protective factor), may also play a role.\nFrom a biological standpoint, several hypotheses have been proposed to explain female susceptibility to AD. Mitochondrial dysfunction plays a central role in AD pathophysiology, but sex differences in mitochondrial function remain poorly defined. Experimental models have shown that male and female animals differ in mitochondrial substrate utilization under stress conditions, though findings vary by context. For instance, in 3xTg-AD mice, sex-specific alterations in brain bioenergetics have been observed: females showed impaired complex I activity in synaptic cortical mitochondria, while non-synaptic mitochondria exhibited enhanced complex II-mediated respiration (\nStojakovic et al., 2021\n).", "doc_items_refs": ["#/texts/622", "#/texts/623", "#/texts/624", "#/texts/625", "#/texts/626", "#/texts/627", "#/texts/628", "#/texts/629", "#/texts/630", "#/texts/631", "#/texts/632"], "page_nos": [], "uuid": "46f323ae-eb96-4cae-a290-dc21629e7c23"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 29, "source_chunk_idxs": [29], "num_tokens": 416, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\n7 Could dual agonism of estrogen and GLP-1 influence Alzheimer's disease prevention?\nIn developmental neurobiology, Arnold proposed three categories of sex differentiation mechanisms: (1) organizational differences driven by fetal hormonal exposure; (2) activational differences induced by the adult hormonal environment; and (3) genetic differences linked to chromosomal content (\nArnold, 2022\n). Studies using transgenic hAPP mouse models have shown that XY animals exhibit more severe clinical courses and earlier mortality compared to XX animals, independent of gonadal sex. This suggests a protective role of the second X chromosome (\nDavis et al., 2020\n), reinforcing the need to consider both genetic and hormonal factors when designing targeted therapies, including those involving hormonal agonists and estrogens for AD prevention (\nLopez-Lee et al., 2024\n).\nThe beneficial effects of estrogens and GLP-1 agonists observed in other metabolic diseases raise the possibility that their combined use could also prevent or delay the onset of Alzheimer's disease. A dual GLP-1-estrogen conjugate (GE) designed to selectively deliver estrogen to GLP-1R + cells induced substantial weight loss in mice without evidence of systemic estrogenic effects, as assessed by uterine weight and growth of estrogen-dependent breast cancer xenografts (\nFinan et al., 2012\n). Genetic studies in mice suggested that these effects were mediated by CNS GLP-1Rs, with increased expression of POMC and leptin receptors in the arcuate nucleus (\nKanoski et al., 2011\n). Selective estrogen delivery to \u03b2-cells via a GE conjugate improved viability in both human and murine \u03b2-cells, again without systemic estrogen exposure (\nSachs et al., 2020\n).", "doc_items_refs": ["#/texts/633", "#/texts/634", "#/texts/635", "#/texts/636", "#/texts/637", "#/texts/638", "#/texts/639", "#/texts/640", "#/texts/641", "#/texts/642", "#/texts/643", "#/texts/644", "#/texts/645", "#/texts/646"], "page_nos": [], "uuid": "8700d51c-4d46-461b-9d50-ef6c4ec2919c"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 30, "source_chunk_idxs": [30], "num_tokens": 464, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\n7 Could dual agonism of estrogen and GLP-1 influence Alzheimer's disease prevention?\nIn another preclinical study, GE demonstrated superior metabolic effects compared to GLP-1-GIP or GLP-1-GIP-glucagon multiagonist therapies in models of polycystic ovary syndrome (PCOS), a condition frequently associated with obesity and insulin resistance. Chronic GE administration in female mice with PCOS significantly improved metabolic profiles, outperforming individual agonists. In the PWA model, GE suppressed hypothalamic expression of BCAP31, a pro-apoptotic protein, and promoted proteins associated with autophagy-critical processes for neuronal function and energy homeostasis. Altered CAMKII expression, which regulates orexigenic neuropeptides like NPY, also reflected compensatory adaptation to weight loss (\nSanchez-Garrido et al., 2024\n).\nPrevious studies in obese rodents and diet-induced obesity models have shown that GE's primary site of action is central, particularly within hypothalamic regions such as the supramammillary nucleus, lateral hypothalamus, and the nucleus of the solitary tract (\nTiano et al., 2015\n). This therapeutic strategy-combining GLP-1 and estrogen receptor activation-was developed to enhance metabolic benefits while limiting systemic estrogen exposure, thereby minimizing reproductive and oncogenic risks. Data confirm that this approach enables tissue-specific action in GLP-1R-expressing regions, avoiding adverse effects in reproductive organs (\nVogel et al., 2016\n).\nProteomic analyses of the hypothalamus following GE treatment revealed downregulation of inflammation-, apoptosis-, and immune-related proteins, and upregulation of pathways related to autophagy, vesicular transport, and intracellular signaling. These changes may help restore central energy homeostasis and explain the marked weight loss observed even at moderate GE doses (\nSchwenk et al., 2015\n).", "doc_items_refs": ["#/texts/647", "#/texts/648", "#/texts/649", "#/texts/650", "#/texts/651", "#/texts/652", "#/texts/653", "#/texts/654", "#/texts/655", "#/texts/656", "#/texts/657"], "page_nos": [], "uuid": "bdeb7646-62b6-4d54-a49e-dd0f7f25ae2a"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 31, "source_chunk_idxs": [31], "num_tokens": 388, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\n8 Conclusion\nAlzheimer's disease remains a complex neurodegenerative disorder with multifactorial origins, including amyloid accumulation, tau pathology, insulin resistance, mitochondrial dysfunction, and chronic inflammation. The evidence reviewed herein underscores the critical role of estrogens in maintaining neuronal homeostasis, particularly through their effects on mitochondrial efficiency, antioxidant defense, and synaptic resilience. In parallel, GLP-1 receptor agonists have demonstrated neuroprotective actions beyond their established metabolic benefits, offering a promising avenue for cognitive preservation in at-risk individuals.\nThe convergence of estrogen and GLP-1 signaling on metabolic and neuroinflammatory pathways supports the rationale for dual-targeted interventions. Preclinical models using GLP-1-estrogen conjugates have shown superior outcomes in metabolic regulation, neuronal viability, and hypothalamic signaling, with reduced systemic estrogenic effects. These findings open a new frontier in personalized neuroendocrine therapy, particularly relevant for postmenopausal women, who bear a disproportionate burden of AD and are often underrepresented in clinical trials.\nFuture research must prioritize the inclusion of sex as a biological variable, explore differential receptor expression and function, and validate the safety and efficacy of dual agonist strategies in humans. As large-scale trials like EVOKE and EVOKE + unfold, integrating insights from estrogen biology could enhance the impact of GLP-1-based therapies in neurodegenerative disease. Ultimately, a deeper understanding of hormone-metabolism interactions may unlock novel, sex-specific strategies for the prevention of Alzheimer's disease.", "doc_items_refs": ["#/texts/659", "#/texts/660", "#/texts/661"], "page_nos": [], "uuid": "f8dd2b5e-2531-45a9-b66f-875f48a919b0"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 32, "source_chunk_idxs": [32, 33, 34, 35, 36], "num_tokens": 391, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nAuthor contributions\nFL: Software, Supervision, Methodology, Data curation, Conceptualization, Validation, Investigation, Formal Analysis, Funding acquisition, Resources, Writing - review and editing, Visualization, Project administration, Writing - original draft. DS: Conceptualization, Methodology, Visualization, Supervision, Writing - review and editing, Software. EA: Methodology, Writing - review and editing, Validation, Investigation, Software, Data curation.\n\nHormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nFunding\nThe author(s) declare that no financial support was received for the research and/or publication of this article.\n\nHormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nConflict of interest\nThe authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n\nHormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nGenerative AI statement\nThe author(s) declare that Generative AI was used in the creation of this manuscript. We used generative AI in order to perfor translation.\n\nHormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nPublisher's note\nAll claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.", "doc_items_refs": ["#/texts/663", "#/texts/665", "#/texts/667", "#/texts/669", "#/texts/671"], "page_nos": [], "uuid": "76fffd50-5fb2-43fb-8810-432d705e2a6c"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 33, "source_chunk_idxs": [37], "num_tokens": 510, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nReferences\nAbdelsalam, S. A., Renu, K., Zahra, H. A., Abdallah, B. M., Ali, E. M., Veeraraghavan, V. P., et al. (2023). Polyphenols mediate neuroprotection in cerebral ischemic stroke-an update.\nNutrients\n15 (5), 1107. doi:10.3390/nu15051107\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nAdams, J. M., Pei, H., Sandoval, D. A., Seeley, R. J., Chang, R. B., Liberles, S. D., et al. (2018). Liraglutide modulates appetite and body weight through glucagon-like peptide 1 receptor-expressing glutamatergic neurons.\nDiabetes\n67 (8), 1538-1548. doi:10.2337/db17-1385\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nAkimoto, H., Negishi, A., Oshima, S., Wakiyama, H., Okita, M., Horii, N., et al. (2020). Antidiabetic drugs for the risk of alzheimer disease in patients with type 2 DM using FAERS.\nAm. J. Alzheimers Dis. Other Demen\n35, 1533317519899546. doi:10.1177/1533317519899546\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nAlaynick, W. A. (2008). Nuclear receptors, mitochondria and lipid metabolism.\nMitochondrion\n8 (4), 329-337. doi:10.1016/j.mito.2008.02.001\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nAranda, A., and Pascual, A. (2001). Nuclear hormone receptors and gene expression.\nPhysiol. Rev.\n81 (3), 1269-1304. doi:10.1152/physrev.2001.81.3.1269", "doc_items_refs": ["#/texts/673", "#/texts/674", "#/texts/675", "#/texts/676", "#/texts/677", "#/texts/678", "#/texts/679", "#/texts/680", "#/texts/681", "#/texts/682", "#/texts/683", "#/texts/684", "#/texts/685", "#/texts/686", "#/texts/687", "#/texts/688", "#/texts/689", "#/texts/690", "#/texts/691", "#/texts/692", "#/texts/693", "#/texts/694", "#/texts/695", "#/texts/696", "#/texts/697", "#/texts/698", "#/texts/699", "#/texts/700", "#/texts/701", "#/texts/702", "#/texts/703", "#/texts/704", "#/texts/705", "#/texts/706", "#/texts/707"], "page_nos": [], "uuid": "191543a6-3ade-4405-ae6f-bdb99326bc4b"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 34, "source_chunk_idxs": [38], "num_tokens": 501, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nReferences\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nArjmand, S., Ilaghi, M., Sisakht, A. K., Guldager, M. B., Wegener, G., Landau, A. M., et al. (2024). Regulation of mitochondrial dysfunction by estrogens and estrogen receptors in Alzheimer's disease: a focused review.\nBasic Clin. Pharmacol. Toxicol.\n135 (2), 115-132. doi:10.1111/bcpt.14035\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nArnold, A. P. (2022). Integrating sex chromosome and endocrine theories to improve teaching of sexual differentiation.\nCold Spring Harb. Perspect. Biol.\n14 (9), a039057. doi:10.1101/cshperspect.a039057\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nArredouani, A. (2025). GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?\nPharmacol. Ther.\n269, 108824. doi:10.1016/j.pharmthera.2025.108824\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nAzcoitia, I., Sierra, A., Veiga, S., Honda, S., Harada, N., and Garcia-Segura, L. M. (2001). Brain aromatase is neuroprotective.\nJ. Neurobiol.\n47 (4), 318-329. doi:10.1002/neu.1038\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nBaggio, L. L., and Drucker, D. J. (2007). Biology of incretins: GLP-1 and GIP.\nGastroenterology\n132 (6), 2131-2157. doi:10.1053/j.gastro.2007.03.054\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/708", "#/texts/709", "#/texts/710", "#/texts/711", "#/texts/712", "#/texts/713", "#/texts/714", "#/texts/715", "#/texts/716", "#/texts/717", "#/texts/718", "#/texts/719", "#/texts/720", "#/texts/721", "#/texts/722", "#/texts/723", "#/texts/724", "#/texts/725", "#/texts/726", "#/texts/727", "#/texts/728", "#/texts/729", "#/texts/730", "#/texts/731", "#/texts/732", "#/texts/733", "#/texts/734", "#/texts/735", "#/texts/736", "#/texts/737", "#/texts/738", "#/texts/739", "#/texts/740", "#/texts/741", "#/texts/742", "#/texts/743", "#/texts/744", "#/texts/745", "#/texts/746", "#/texts/747", "#/texts/748", "#/texts/749", "#/texts/750", "#/texts/751", "#/texts/752"], "page_nos": [], "uuid": "a9408df8-437f-4d00-9e25-9e3c47aaba0e"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 35, "source_chunk_idxs": [39], "num_tokens": 446, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nReferences\nBai, R., Guo, J., Ye, X. Y., Xie, Y., and Xie, T. (2022). Oxidative stress: the core pathogenesis and mechanism of Alzheimer's disease.\nAgeing Res. Rev.\n77, 101619. doi:10.1016/j.arr.2022.101619\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nBaloyannis, S. J., Mavroudis, I., Baloyannis, I. S., and Costa, V. G. (2016). Mammillary bodies in Alzheimer's disease: a golgi and electron microscope study.\nAm. J. Alzheimers Dis. Other Demen\n31 (3), 247-256. doi:10.1177/1533317515602548\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nBaloyannis, S. J., Mavroudis, I., Mitilineos, D., Baloyannis, I. S., and Costa, V. G. (2015). The hypothalamus in Alzheimer's disease: a Golgi and electron microscope study.\nAm. J. Alzheimers Dis. Other Demen\n30 (5), 478-487. doi:10.1177/1533317514556876\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nBassil, F., Fernagut, P. O., Bezard, E., and Meissner, W. G. (2014). Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification?\nProg. Neurobiol.\n118, 1-18. doi:10.1016/j.pneurobio.2014.02.005\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/753", "#/texts/754", "#/texts/755", "#/texts/756", "#/texts/757", "#/texts/758", "#/texts/759", "#/texts/760", "#/texts/761", "#/texts/762", "#/texts/763", "#/texts/764", "#/texts/765", "#/texts/766", "#/texts/767", "#/texts/768", "#/texts/769", "#/texts/770", "#/texts/771", "#/texts/772", "#/texts/773", "#/texts/774", "#/texts/775", "#/texts/776", "#/texts/777", "#/texts/778", "#/texts/779", "#/texts/780", "#/texts/781", "#/texts/782", "#/texts/783", "#/texts/784"], "page_nos": [], "uuid": "e29e16e8-2599-4c4e-a93d-98083aaa57a5"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 36, "source_chunk_idxs": [40], "num_tokens": 433, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nReferences\nBenziger, C. P., Roth, G. A., and Moran, A. E. (2016). The global burden of disease study and the preventable burden of NCD.\nGlob. Heart\n11 (4), 393-397. doi:10.1016/j.gheart.2016.10.024\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nBernabe-Ortiz, A., and Carrillo-Larco, R. M. (2022). Urbanization, altitude and cardiovascular risk.\nGlob. Heart\n17 (1), 42. doi:10.5334/gh.1130\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nBlakemore, J., and Naftolin, F. (2016). Aromatase: contributions to physiology and disease in women and men.\nPhysiol. (Bethesda)\n31 (4), 258-269. doi:10.1152/physiol.00054.2015\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nBorchers, S., and Skibicka, K. P. (2025). GLP-1 and its analogs: does sex matter?\nEndocrinology\n166 (2), bqae165. doi:10.1210/endocr/bqae165\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nBrann, D. W., Lu, Y., Wang, J., Sareddy, G. R., Pratap, U. P., Zhang, Q., et al. (2022). Brain-derived estrogen and neurological disorders.\nBiol. (Basel)\n11 (12), 1698. doi:10.3390/biology11121698\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/785", "#/texts/786", "#/texts/787", "#/texts/788", "#/texts/789", "#/texts/790", "#/texts/791", "#/texts/792", "#/texts/793", "#/texts/794", "#/texts/795", "#/texts/796", "#/texts/797", "#/texts/798", "#/texts/799", "#/texts/800", "#/texts/801", "#/texts/802", "#/texts/803", "#/texts/804", "#/texts/805", "#/texts/806", "#/texts/807", "#/texts/808", "#/texts/809", "#/texts/810", "#/texts/811", "#/texts/812", "#/texts/813", "#/texts/814", "#/texts/815", "#/texts/816", "#/texts/817", "#/texts/818", "#/texts/819", "#/texts/820", "#/texts/821", "#/texts/822", "#/texts/823", "#/texts/824"], "page_nos": [], "uuid": "42a743b0-a05c-4719-860b-b41dc98f4ef1"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 37, "source_chunk_idxs": [41], "num_tokens": 459, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nReferences\nBrewer, G. J., Herrera, R. A., Philipp, S., Sosna, J., Reyes-Ruiz, J. M., and Glabe, C. G. (2020). Age-related intraneuronal aggregation of amyloid-beta in endosomes, mitochondria, autophagosomes, and lysosomes.\nJ. Alzheimers Dis.\n73 (1), 229-246. doi:10.3233/JAD-190835\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nBudreviciute, A., Damiati, S., Sabir, D. K., Onder, K., Schuller-Goetzburg, P., Plakys, G., et al. (2020). Management and prevention strategies for non-communicable diseases (NCDs) and their risk factors.\nFront. Public Health\n8, 574111. doi:10.3389/fpubh.2020.574111\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nBullock, B. P., Heller, R. S., and Habener, J. F. (1996). Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor.\nEndocrinology\n137 (7), 2968-2978. doi:10.1210/endo.137.7.8770921\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nButeau, J., Foisy, S., Joly, E., and Prentki, M. (2003). Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor.\nDiabetes\n52 (1), 124-132. doi:10.2337/diabetes.52.1.124\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/825", "#/texts/826", "#/texts/827", "#/texts/828", "#/texts/829", "#/texts/830", "#/texts/831", "#/texts/832", "#/texts/833", "#/texts/834", "#/texts/835", "#/texts/836", "#/texts/837", "#/texts/838", "#/texts/839", "#/texts/840", "#/texts/841", "#/texts/842", "#/texts/843", "#/texts/844", "#/texts/845", "#/texts/846", "#/texts/847", "#/texts/848", "#/texts/849", "#/texts/850", "#/texts/851", "#/texts/852", "#/texts/853", "#/texts/854", "#/texts/855", "#/texts/856"], "page_nos": [], "uuid": "4e515744-8f97-412b-b2fe-6229373b7043"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 38, "source_chunk_idxs": [42], "num_tokens": 430, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nReferences\nChang, C. C., Lin, T. C., Ho, H. L., Kuo, C. Y., Li, H. H., Korolenko, T. A., et al. (2018). GLP-1 analogue liraglutide attenuates mutant huntingtin-induced neurotoxicity by restoration of neuronal insulin signaling.\nInt. J. Mol. Sci.\n19 (9), 2505. doi:10.3390/ijms19092505\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nCorreia, S. C., Santos, R. X., Carvalho, C., Cardoso, S., Candeias, E., Santos, M. S., et al. (2012). Insulin signaling, glucose metabolism and mitochondria: major players in Alzheimer's disease and diabetes interrelation.\nBrain Res.\n1441, 64-78. doi:10.1016/j.brainres.2011.12.063\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nCraft, S., and Watson, G. S. (2004). Insulin and neurodegenerative disease: shared and specific mechanisms.\nLancet Neurol.\n3 (3), 169-178. doi:10.1016/S1474-4422(04)00681-7\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nCrook, H., and Edison, P. (2024). Incretin mimetics as potential disease modifying treatment for Alzheimer's disease.\nJ. Alzheimers Dis.\n101 (s1), S357-S370. doi:10.3233/JAD-240730\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/857", "#/texts/858", "#/texts/859", "#/texts/860", "#/texts/861", "#/texts/862", "#/texts/863", "#/texts/864", "#/texts/865", "#/texts/866", "#/texts/867", "#/texts/868", "#/texts/869", "#/texts/870", "#/texts/871", "#/texts/872", "#/texts/873", "#/texts/874", "#/texts/875", "#/texts/876", "#/texts/877", "#/texts/878", "#/texts/879", "#/texts/880", "#/texts/881", "#/texts/882", "#/texts/883", "#/texts/884", "#/texts/885", "#/texts/886", "#/texts/887", "#/texts/888"], "page_nos": [], "uuid": "00db8c59-6cb5-4dfa-852a-a445f6be097a"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 39, "source_chunk_idxs": [43], "num_tokens": 418, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nReferences\nCukierman-Yaffe, T., Gerstein, H. C., Colhoun, H. M., Diaz, R., Garcia-Perez, L. E., Lakshmanan, M., et al. (2020). Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial.\nLancet Neurol.\n19 (7), 582-590. doi:10.1016/S1474-4422(20)30173-3\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nCummings, J. L., Atri, A., Feldman, H. H., Hansson, O., Sano, M., Knop, F. K., et al. (2025). Evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease.\nAlzheimers Res. Ther.\n17 (1), 14. doi:10.1186/s13195-024-01666-7\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nDai, C., Hang, Y., Shostak, A., Poffenberger, G., Hart, N., Prasad, N., et al. (2017). Age-dependent human beta cell proliferation induced by glucagon-like peptide 1 and calcineurin signaling.\nJ. Clin. Invest\n127 (10), 3835-3844. doi:10.1172/JCI91761\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/889", "#/texts/890", "#/texts/891", "#/texts/892", "#/texts/893", "#/texts/894", "#/texts/895", "#/texts/896", "#/texts/897", "#/texts/898", "#/texts/899", "#/texts/900", "#/texts/901", "#/texts/902", "#/texts/903", "#/texts/904", "#/texts/905", "#/texts/906", "#/texts/907", "#/texts/908", "#/texts/909", "#/texts/910", "#/texts/911", "#/texts/912"], "page_nos": [], "uuid": "dbd3afb1-f681-460c-922c-70822509feda"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 40, "source_chunk_idxs": [44], "num_tokens": 407, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nReferences\nDavis, E. J., Broestl, L., Abdulai-Saiku, S., Worden, K., Bonham, L. W., Minones-Moyano, E., et al. (2020). A second X chromosome contributes to resilience in a mouse model of Alzheimer's disease.\nSci. Transl. Med.\n12 (558), eaaz5677. doi:10.1126/scitranslmed.aaz5677\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nDemers-Lamarche, J., Guillebaud, G., Tlili, M., Todkar, K., Belanger, N., Grondin, M., et al. (2016). Loss of mitochondrial function impairs lysosomes.\nJ. Biol. Chem.\n291 (19), 10263-10276. doi:10.1074/jbc.M115.695825\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nDrucker, D. J. (2006). The biology of incretin hormones.\nCell Metab.\n3 (3), 153-165. doi:10.1016/j.cmet.2006.01.004\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nDrucker, D. J., and Holst, J. J. (2023). The expanding incretin universe: from basic biology to clinical translation.\nDiabetologia\n66 (10), 1765-1779. doi:10.1007/s00125-023-05906-7\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/913", "#/texts/914", "#/texts/915", "#/texts/916", "#/texts/917", "#/texts/918", "#/texts/919", "#/texts/920", "#/texts/921", "#/texts/922", "#/texts/923", "#/texts/924", "#/texts/925", "#/texts/926", "#/texts/927", "#/texts/928", "#/texts/929", "#/texts/930", "#/texts/931", "#/texts/932", "#/texts/933", "#/texts/934", "#/texts/935", "#/texts/936", "#/texts/937", "#/texts/938", "#/texts/939", "#/texts/940", "#/texts/941", "#/texts/942", "#/texts/943", "#/texts/944"], "page_nos": [], "uuid": "28bb6a7d-4432-4d1e-adc0-79377729da62"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 41, "source_chunk_idxs": [45], "num_tokens": 475, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nReferences\nDrucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., and Habener, J. F. (1987). Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line.\nProc. Natl. Acad. Sci. U. S. A.\n84 (10), 3434-3438. doi:10.1073/pnas.84.10.3434\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nDu, H., Guo, L., Yan, S., Sosunov, A. A., McKhann, G. M., and Yan, S. S. (2010). Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model.\nProc. Natl. Acad. Sci. U. S. A.\n107 (43), 18670-18675. doi:10.1073/pnas.1006586107\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nDu, H., Meng, X., Yao, Y., and Xu, J. (2022). The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer's disease.\nFront. Endocrinol. (Lausanne)\n13, 1033479. doi:10.3389/fendo.2022.1033479\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nElson, J. L., Herrnstadt, C., Preston, G., Thal, L., Morris, C. M., Edwardson, J. A., et al. (2006). Does the mitochondrial genome play a role in the etiology of Alzheimer's disease?\nHum. Genet.\n119 (3), 241-254. doi:10.1007/s00439-005-0123-8\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/945", "#/texts/946", "#/texts/947", "#/texts/948", "#/texts/949", "#/texts/950", "#/texts/951", "#/texts/952", "#/texts/953", "#/texts/954", "#/texts/955", "#/texts/956", "#/texts/957", "#/texts/958", "#/texts/959", "#/texts/960", "#/texts/961", "#/texts/962", "#/texts/963", "#/texts/964", "#/texts/965", "#/texts/966", "#/texts/967", "#/texts/968", "#/texts/969", "#/texts/970", "#/texts/971", "#/texts/972", "#/texts/973", "#/texts/974", "#/texts/975", "#/texts/976"], "page_nos": [], "uuid": "6552c8ac-c0b4-4a11-be20-e14cdbb305be"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 42, "source_chunk_idxs": [46], "num_tokens": 449, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nReferences\nFemminella, G. D., Frangou, E., Love, S. B., Busza, G., Holmes, C., Ritchie, C., et al. (2019). Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).\nTrials\n20 (1), 191. doi:10.1186/s13063-019-3259-x\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nFernandez-Mosquera, L., Diogo, C. V., Yambire, K. F., Santos, G. L., Luna Sanchez, M., Benit, P., et al. (2017). Acute and chronic mitochondrial respiratory chain deficiency differentially regulate lysosomal biogenesis.\nSci. Rep.\n7, 45076. doi:10.1038/srep45076\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nFinan, B., Yang, B., Ottaway, N., Stemmer, K., Muller, T. D., Yi, C. X., et al. (2012). Targeted estrogen delivery reverses the metabolic syndrome.\nNat. Med.\n18 (12), 1847-1856. doi:10.1038/nm.3009\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nFlorian, H., Wang, D., Arnold, S. E., Boada, M., Guo, Q., Jin, Z., et al. (2023). Tilavonemab in early Alzheimer's disease: results from a phase 2, randomized, double-blind study.\nBrain\n146 (6), 2275-2284. doi:10.1093/brain/awad024\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/977", "#/texts/978", "#/texts/979", "#/texts/980", "#/texts/981", "#/texts/982", "#/texts/983", "#/texts/984", "#/texts/985", "#/texts/986", "#/texts/987", "#/texts/988", "#/texts/989", "#/texts/990", "#/texts/991", "#/texts/992", "#/texts/993", "#/texts/994", "#/texts/995", "#/texts/996", "#/texts/997", "#/texts/998", "#/texts/999", "#/texts/1000", "#/texts/1001", "#/texts/1002", "#/texts/1003", "#/texts/1004", "#/texts/1005", "#/texts/1006", "#/texts/1007", "#/texts/1008"], "page_nos": [], "uuid": "c85a1d5c-475f-405a-b5fb-2e706e2ea5f4"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 43, "source_chunk_idxs": [47], "num_tokens": 448, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nReferences\nFrick, K. M., Kim, J., Tuscher, J. J., and Fortress, A. M. (2015). Sex steroid hormones matter for learning and memory: estrogenic regulation of hippocampal function in male and female rodents.\nLearn Mem.\n22 (9), 472-493. doi:10.1101/lm.037267.114\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nGejl, M., Gjedde, A., Egefjord, L., Moller, A., Hansen, S. B., Vang, K., et al. (2016). In Alzheimer's disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial.\nFront. Aging Neurosci.\n8, 108. doi:10.3389/fnagi.2016.00108\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nGillies, G. E., and McArthur, S. (2010). Estrogen actions in the brain and the basis for differential action in men and women: a case for sex-specific medicines.\nPharmacol. Rev.\n62 (2), 155-198. doi:10.1124/pr.109.002071\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nGrimm, M. O. W., Michaelson, D. M., and Hartmann, T. (2017). Omega-3 fatty acids, lipids, and apoE lipidation in Alzheimer's disease: a rationale for multi-nutrient dementia prevention.\nJ. Lipid Res.\n58 (11), 2083-2101. doi:10.1194/jlr.R076331\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/1009", "#/texts/1010", "#/texts/1011", "#/texts/1012", "#/texts/1013", "#/texts/1014", "#/texts/1015", "#/texts/1016", "#/texts/1017", "#/texts/1018", "#/texts/1019", "#/texts/1020", "#/texts/1021", "#/texts/1022", "#/texts/1023", "#/texts/1024", "#/texts/1025", "#/texts/1026", "#/texts/1027", "#/texts/1028", "#/texts/1029", "#/texts/1030", "#/texts/1031", "#/texts/1032", "#/texts/1033", "#/texts/1034", "#/texts/1035", "#/texts/1036", "#/texts/1037", "#/texts/1038", "#/texts/1039", "#/texts/1040"], "page_nos": [], "uuid": "9de2bfc6-a94a-4111-8d30-b0badbfe0c6e"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 44, "source_chunk_idxs": [48], "num_tokens": 500, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nReferences\nGuo, J. L., Braun, D., Fitzgerald, G. A., Hsieh, Y. T., Rouge, L., Litvinchuk, A., et al. (2025). Decreased lipidated ApoE-receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes.\nCell\n188 (1), 187-206.e26. doi:10.1016/j.cell.2024.10.027\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nHaas, E., Bhattacharya, I., Brailoiu, E., Damjanovic, M., Brailoiu, G. C., Gao, X., et al. (2009). Regulatory role of G protein-coupled estrogen receptor for vascular function and obesity.\nCirc. Res.\n104 (3), 288-291. doi:10.1161/CIRCRESAHA.108.190892\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nHan, X. (2005). Lipid alterations in the earliest clinically recognizable stage of Alzheimer's disease: implication of the role of lipids in the pathogenesis of Alzheimer's disease.\nCurr. Alzheimer Res.\n2 (1), 65-77. doi:10.2174/1567205052772786\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nHarris, E. (2024). Poll: roughly 12% of US adults have used a GLP-1 drug, even if unaffordable.\nJAMA\n332 (1), 8. doi:10.1001/jama.2024.10333\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nHauser, P. S., Narayanaswami, V., and Ryan, R. O. (2011). Apolipoprotein E: from lipid transport to neurobiology.\nProg. Lipid Res.\n50 (1), 62-74. doi:10.1016/j.plipres.2010.09.001\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/1041", "#/texts/1042", "#/texts/1043", "#/texts/1044", "#/texts/1045", "#/texts/1046", "#/texts/1047", "#/texts/1048", "#/texts/1049", "#/texts/1050", "#/texts/1051", "#/texts/1052", "#/texts/1053", "#/texts/1054", "#/texts/1055", "#/texts/1056", "#/texts/1057", "#/texts/1058", "#/texts/1059", "#/texts/1060", "#/texts/1061", "#/texts/1062", "#/texts/1063", "#/texts/1064", "#/texts/1065", "#/texts/1066", "#/texts/1067", "#/texts/1068", "#/texts/1069", "#/texts/1070", "#/texts/1071", "#/texts/1072", "#/texts/1073", "#/texts/1074", "#/texts/1075", "#/texts/1076", "#/texts/1077", "#/texts/1078", "#/texts/1079", "#/texts/1080"], "page_nos": [], "uuid": "40e4cb40-3bc1-4ca8-9dd0-01472d71a6ac"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 45, "source_chunk_idxs": [49], "num_tokens": 467, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nReferences\nHernandez-Rodriguez, M., Clemente, C. F., Macias-Perez, M. E., Rodriguez-Fonseca, R. A., Vazquez, M. I. N., Martinez, J., et al. (2022). Contribution of hyperglycemia-induced changes in microglia to Alzheimer's disease pathology.\nPharmacol. Rep.\n74 (5), 832-846. doi:10.1007/s43440-022-00405-9\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nHestiantoro, A., and Swaab, D. F. (2004). Changes in estrogen receptor-alpha and -beta in the infundibular nucleus of the human hypothalamus are related to the occurrence of Alzheimer's disease neuropathology.\nJ. Clin. Endocrinol. Metab.\n89 (4), 1912-1925. doi:10.1210/jc.2003-030862\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nHewitt, S. C., Winuthayanon, W., Lierz, S. L., Hamilton, K. J., Donoghue, L. J., Ramsey, J. T., et al. (2017). Role of ER\u03b1 in mediating female uterine transcriptional responses to IGF1.\nEndocrinology\n158 (8), 2427-2435. doi:10.1210/en.2017-00349\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nHolscher, C. (2018). Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models.\nNeuropharmacology\n136 (Pt B), 251-259. doi:10.1016/j.neuropharm.2018.01.040\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/1081", "#/texts/1082", "#/texts/1083", "#/texts/1084", "#/texts/1085", "#/texts/1086", "#/texts/1087", "#/texts/1088", "#/texts/1089", "#/texts/1090", "#/texts/1091", "#/texts/1092", "#/texts/1093", "#/texts/1094", "#/texts/1095", "#/texts/1096", "#/texts/1097", "#/texts/1098", "#/texts/1099", "#/texts/1100", "#/texts/1101", "#/texts/1102", "#/texts/1103", "#/texts/1104", "#/texts/1105", "#/texts/1106", "#/texts/1107", "#/texts/1108", "#/texts/1109", "#/texts/1110", "#/texts/1111", "#/texts/1112"], "page_nos": [], "uuid": "52d3836e-d310-4466-8268-fce02087c444"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 46, "source_chunk_idxs": [50], "num_tokens": 449, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nReferences\nHoulden, H., Crook, R., Backhovens, H., Prihar, G., Baker, M., Hutton, M., et al. (1998). ApoE genotype is a risk factor in nonpresenilin early-onset alzheimer's disease families.\nAm. J. Med. Genet.\n81 (1), 117-121. doi:10.1002/(sici)1096-8628(19980207)81:13.0.co;2-m\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nHuang, Y., and Mahley, R. W. (2014). Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases.\nNeurobiol. Dis . 72 Pt\nA, 3-12. doi:10.1016/j.nbd.2014.08.025\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nIrwin, R. W., Yao, J., To, J., Hamilton, R. T., Cadenas, E., and Brinton, R. D. (2012). Selective oestrogen receptor modulators differentially potentiate brain mitochondrial function.\nJ. Neuroendocrinol.\n24 (1), 236-248. doi:10.1111/j.1365-2826.2011.02251.x\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nJackson, R. J., Hyman, B. T., and Serrano-Pozo, A. (2024). Multifaceted roles of APOE in Alzheimer disease.\nNat. Rev. Neurol.\n20 (8), 457-474. doi:10.1038/s41582-024-00988-2\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/1113", "#/texts/1114", "#/texts/1115", "#/texts/1116", "#/texts/1117", "#/texts/1118", "#/texts/1119", "#/texts/1120", "#/texts/1121", "#/texts/1122", "#/texts/1123", "#/texts/1124", "#/texts/1125", "#/texts/1126", "#/texts/1127", "#/texts/1128", "#/texts/1129", "#/texts/1130", "#/texts/1131", "#/texts/1132", "#/texts/1133", "#/texts/1134", "#/texts/1135", "#/texts/1136", "#/texts/1137", "#/texts/1138", "#/texts/1139", "#/texts/1140", "#/texts/1141", "#/texts/1142", "#/texts/1143", "#/texts/1144"], "page_nos": [], "uuid": "fe02aa4f-3a3d-4f22-bc28-56a27083e926"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 47, "source_chunk_idxs": [51], "num_tokens": 507, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nReferences\nJastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., et al. (2022). Tirzepatide once weekly for the treatment of obesity.\nN. Engl. J. Med.\n387 (3), 205-216. doi:10.1056/NEJMoa2206038\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nJellinger, K. A. (2024). Depression and anxiety in multiple sclerosis. Review of a fatal combination.\nJ. Neural Transm. (Vienna)\n131 (8), 847-869. doi:10.1007/s00702-024-02792-0\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nJiang, Y., Wang, Z., Ma, B., Fan, L., Yi, N., Lu, B., et al. (2018). GLP-1 improves adipocyte insulin sensitivity following induction of endoplasmic reticulum stress.\nFront. Pharmacol.\n9, 1168. doi:10.3389/fphar.2018.01168\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nJohri, A., Roncati, L., and Lizcano, F. (2024). Editorial: endocrine disruptors and diseases of brain and mind: past and prelude.\nFront. Endocrinol. (Lausanne)\n15, 1362519. doi:10.3389/fendo.2024.1362519\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nJoshi, A. U., Saw, N. L., Shamloo, M., and Mochly-Rosen, D. (2018). Drp1/Fis1 interaction mediates mitochondrial dysfunction, bioenergetic failure and cognitive decline in Alzheimer's disease.\nOncotarget\n9 (5), 6128-6143. doi:10.18632/oncotarget.23640\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/1145", "#/texts/1146", "#/texts/1147", "#/texts/1148", "#/texts/1149", "#/texts/1150", "#/texts/1151", "#/texts/1152", "#/texts/1153", "#/texts/1154", "#/texts/1155", "#/texts/1156", "#/texts/1157", "#/texts/1158", "#/texts/1159", "#/texts/1160", "#/texts/1161", "#/texts/1162", "#/texts/1163", "#/texts/1164", "#/texts/1165", "#/texts/1166", "#/texts/1167", "#/texts/1168", "#/texts/1169", "#/texts/1170", "#/texts/1171", "#/texts/1172", "#/texts/1173", "#/texts/1174", "#/texts/1175", "#/texts/1176", "#/texts/1177", "#/texts/1178", "#/texts/1179", "#/texts/1180", "#/texts/1181", "#/texts/1182", "#/texts/1183", "#/texts/1184"], "page_nos": [], "uuid": "e2401ad3-aab6-4a69-8ccb-342d4c7aab46"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 48, "source_chunk_idxs": [52], "num_tokens": 508, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nReferences\nKanoski, S. E., Fortin, S. M., Arnold, M., Grill, H. J., and Hayes, M. R. (2011). Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4.\nEndocrinology\n152 (8), 3103-3112. doi:10.1210/en.2011-0174\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nKapogiannis, D., Mustapic, M., Shardell, M. D., Berkowitz, S. T., Diehl, T. C., Spangler, R. D., et al. (2019). Association of extracellular vesicle biomarkers with alzheimer disease in the Baltimore longitudinal study of aging.\nJAMA Neurol.\n76 (11), 1340-1351. doi:10.1001/jamaneurol.2019.2462\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nKarim, H., Kim, S. H., Lapato, A. S., Yasui, N., Katzenellenbogen, J. A., and Tiwari-Woodruff, S. K. (2018). Increase in chemokine CXCL1 by ER\u03b2 ligand treatment is a key mediator in promoting axon myelination.\nProc. Natl. Acad. Sci. U. S. A.\n115 (24), 6291-6296. doi:10.1073/pnas.1721732115\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nKastin, A. J., and Akerstrom, V. (2003). Entry of exendin-4 into brain is rapid but may be limited at high doses.\nInt. J. Obes. Relat. Metab. Disord.\n27 (3), 313-318. doi:10.1038/sj.ijo.0802206\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/1185", "#/texts/1186", "#/texts/1187", "#/texts/1188", "#/texts/1189", "#/texts/1190", "#/texts/1191", "#/texts/1192", "#/texts/1193", "#/texts/1194", "#/texts/1195", "#/texts/1196", "#/texts/1197", "#/texts/1198", "#/texts/1199", "#/texts/1200", "#/texts/1201", "#/texts/1202", "#/texts/1203", "#/texts/1204", "#/texts/1205", "#/texts/1206", "#/texts/1207", "#/texts/1208", "#/texts/1209", "#/texts/1210", "#/texts/1211", "#/texts/1212", "#/texts/1213", "#/texts/1214", "#/texts/1215", "#/texts/1216"], "page_nos": [], "uuid": "2d6af9ce-b6ea-4c56-a1bb-1530aa445a69"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 49, "source_chunk_idxs": [53], "num_tokens": 502, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nReferences\nKellar, D., and Craft, S. (2020). Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches.\nLancet Neurol.\n19 (9), 758-766. doi:10.1016/S1474-4422(20)30231-3\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nKelly, M. J., and Ronnekleiv, O. K. (2012). Membrane-initiated actions of estradiol that regulate reproduction, energy balance and body temperature.\nFront. Neuroendocrinol.\n33 (4), 376-387. doi:10.1016/j.yfrne.2012.07.002\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nKim, C. K., Torcaso, A., Asimes, A., Chung, W. C. J., and Pak, T. R. (2018). Structural and functional characteristics of oestrogen receptor beta splice variants: implications for the ageing brain.\nJ. Neuroendocrinol.\n30 (2). doi:10.1111/jne.12488\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nKinney, J. W., Bemiller, S. M., Murtishaw, A. S., Leisgang, A. M., Salazar, A. M., and Lamb, B. T. (2018). Inflammation as a central mechanism in Alzheimer's disease.\nAlzheimers Dement. (N Y)\n4, 575-590. doi:10.1016/j.trci.2018.06.014\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nKnopman, D. S., Amieva, H., Petersen, R. C., Chetelat, G., Holtzman, D. M., Hyman, B. T., et al. (2021). Alzheimer disease.\nNat. Rev. Dis. Prim.\n7 (1), 33. doi:10.1038/s41572-021-00269-y", "doc_items_refs": ["#/texts/1217", "#/texts/1218", "#/texts/1219", "#/texts/1220", "#/texts/1221", "#/texts/1222", "#/texts/1223", "#/texts/1224", "#/texts/1225", "#/texts/1226", "#/texts/1227", "#/texts/1228", "#/texts/1229", "#/texts/1230", "#/texts/1231", "#/texts/1232", "#/texts/1233", "#/texts/1234", "#/texts/1235", "#/texts/1236", "#/texts/1237", "#/texts/1238", "#/texts/1239", "#/texts/1240", "#/texts/1241", "#/texts/1242", "#/texts/1243", "#/texts/1244", "#/texts/1245", "#/texts/1246", "#/texts/1247", "#/texts/1248", "#/texts/1249", "#/texts/1250", "#/texts/1251"], "page_nos": [], "uuid": "e7d21d0e-c754-4d35-b35f-dca6e0544b9b"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 50, "source_chunk_idxs": [54], "num_tokens": 476, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nReferences\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nKober, D. L., and Brett, T. J. (2017). TREM2-Ligand interactions in Health and disease.\nJ. Mol. Biol.\n429 (11), 1607-1629. doi:10.1016/j.jmb.2017.04.004\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nKreymann, B., Williams, G., Ghatei, M. A., and Bloom, S. R. (1987). Glucagon-like peptide-1 7-36: a physiological incretin in man.\nLancet\n2 (8571), 1300-1304. doi:10.1016/s0140-6736(87)91194-9\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nKruijver, F. P., Balesar, R., Espila, A. M., Unmehopa, U. A., and Swaab, D. F. (2003). Estrogen-receptor-beta distribution in the human hypothalamus: similarities and differences with ER alpha distribution.\nJ. Comp. Neurol.\n466 (2), 251-277. doi:10.1002/cne.10899\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nLaflamme, N., Nappi, R. E., Drolet, G., Labrie, C., and Rivest, S. (1998). Expression and neuropeptidergic characterization of estrogen receptors (ERalpha and ERbeta) throughout the rat brain: anatomical evidence of distinct roles of each subtype.\nJ. Neurobiol.\n36 (3), 357-378. doi:10.1002/(sici)1097-4695(19980905)36:33.0.co;2-v\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/1252", "#/texts/1253", "#/texts/1254", "#/texts/1255", "#/texts/1256", "#/texts/1257", "#/texts/1258", "#/texts/1259", "#/texts/1260", "#/texts/1261", "#/texts/1262", "#/texts/1263", "#/texts/1264", "#/texts/1265", "#/texts/1266", "#/texts/1267", "#/texts/1268", "#/texts/1269", "#/texts/1270", "#/texts/1271", "#/texts/1272", "#/texts/1273", "#/texts/1274", "#/texts/1275", "#/texts/1276", "#/texts/1277", "#/texts/1278", "#/texts/1279", "#/texts/1280", "#/texts/1281", "#/texts/1282", "#/texts/1283", "#/texts/1284", "#/texts/1285", "#/texts/1286", "#/texts/1287", "#/texts/1288"], "page_nos": [], "uuid": "49962410-93cd-49fb-97e8-d789c15ba8f7"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 51, "source_chunk_idxs": [55], "num_tokens": 509, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nReferences\nLane, C. A., Hardy, J., and Schott, J. M. (2018). Alzheimer's disease.\nEur. J. Neurol.\n25 (1), 59-70. doi:10.1111/ene.13439\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nLane, D. J. R., Ayton, S., and Bush, A. I. (2018). Iron and Alzheimer's disease: an update on emerging mechanisms.\nJ. Alzheimers Dis.\n64 (s1), S379-S395. doi:10.3233/JAD-179944\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nLeclere, R., Torregrosa-Munumer, R., Kireev, R., Garcia, C., Vara, E., Tresguerres, J. A., et al. (2013). Effect of estrogens on base excision repair in brain and liver mitochondria of aged female rats.\nBiogerontology\n14 (4), 383-394. doi:10.1007/s10522-013-9431-x\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nLiang, Y., Dore, V., Rowe, C. C., and Krishnadas, N. (2024). Clinical evidence for GLP-1 receptor agonists in Alzheimer's disease: a systematic review.\nJ. Alzheimers Dis. Rep.\n8 (1), 777-789. doi:10.3233/ADR-230181\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nLivingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., et al. (2020). Dementia prevention, intervention, and care: 2020 report of the Lancet Commission.\nLancet\n396 (10248), 413-446. doi:10.1016/S0140-6736(20)30367-6\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/1289", "#/texts/1290", "#/texts/1291", "#/texts/1292", "#/texts/1293", "#/texts/1294", "#/texts/1295", "#/texts/1296", "#/texts/1297", "#/texts/1298", "#/texts/1299", "#/texts/1300", "#/texts/1301", "#/texts/1302", "#/texts/1303", "#/texts/1304", "#/texts/1305", "#/texts/1306", "#/texts/1307", "#/texts/1308", "#/texts/1309", "#/texts/1310", "#/texts/1311", "#/texts/1312", "#/texts/1313", "#/texts/1314", "#/texts/1315", "#/texts/1316", "#/texts/1317", "#/texts/1318", "#/texts/1319", "#/texts/1320", "#/texts/1321", "#/texts/1322", "#/texts/1323", "#/texts/1324", "#/texts/1325", "#/texts/1326", "#/texts/1327", "#/texts/1328"], "page_nos": [], "uuid": "cf04dccf-2526-4c96-b914-5164106e6ceb"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 52, "source_chunk_idxs": [56], "num_tokens": 459, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nReferences\nLizcano, F. (2022). Roles of estrogens, estrogen-like compounds, and endocrine disruptors in adipocytes.\nFront. Endocrinol. (Lausanne)\n13, 921504. doi:10.3389/fendo.2022.921504\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nLizcano, F., and Guzman, G. (2014). Estrogen deficiency and the origin of obesity during menopause.\nBiomed. Res. Int.\n2014, 757461. doi:10.1155/2014/757461\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nLonard, D. M., and O'Malley, B. W. (2006). The expanding cosmos of nuclear receptor coactivators.\nCell\n125 (3), 411-414. doi:10.1016/j.cell.2006.04.021\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nLong, J., He, P., Shen, Y., and Li, R. (2012). New evidence of mitochondria dysfunction in the female Alzheimer's disease brain: deficiency of estrogen receptor-\u03b2.\nJ. Alzheimers Dis.\n30 (3), 545-558. doi:10.3233/JAD-2012-120283\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nLoomba, R., Hartman, M. L., Lawitz, E. J., Vuppalanchi, R., Boursier, J., Bugianesi, E., et al. (2024). Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis.\nN. Engl. J. Med.\n391 (4), 299-310. doi:10.1056/NEJMoa2401943\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/1329", "#/texts/1330", "#/texts/1331", "#/texts/1332", "#/texts/1333", "#/texts/1334", "#/texts/1335", "#/texts/1336", "#/texts/1337", "#/texts/1338", "#/texts/1339", "#/texts/1340", "#/texts/1341", "#/texts/1342", "#/texts/1343", "#/texts/1344", "#/texts/1345", "#/texts/1346", "#/texts/1347", "#/texts/1348", "#/texts/1349", "#/texts/1350", "#/texts/1351", "#/texts/1352", "#/texts/1353", "#/texts/1354", "#/texts/1355", "#/texts/1356", "#/texts/1357", "#/texts/1358", "#/texts/1359", "#/texts/1360", "#/texts/1361", "#/texts/1362", "#/texts/1363", "#/texts/1364", "#/texts/1365", "#/texts/1366", "#/texts/1367", "#/texts/1368"], "page_nos": [], "uuid": "1d055c63-10ee-4c86-86ab-df8852aac104"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 53, "source_chunk_idxs": [57], "num_tokens": 443, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nReferences\nLopez-Lee, C., Torres, E. R. S., Carling, G., and Gan, L. (2024). Mechanisms of sex differences in Alzheimer's disease.\nNeuron\n112 (8), 1208-1221. doi:10.1016/j.neuron.2024.01.024\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nLuo, J., and Liu, D. (2020). Does GPER really function as a G protein-coupled estrogen receptor\nin vivo\n?\nFront. Endocrinol. (Lausanne)\n11, 148. doi:10.3389/fendo.2020.00148\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nManczak, M., Calkins, M. J., and Reddy, P. H. (2011). Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage.\nHum. Mol. Genet.\n20 (13), 2495-2509. doi:10.1093/hmg/ddr139\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nMarino, M., Galluzzo, P., and Ascenzi, P. (2006). Estrogen signaling multiple pathways to impact gene transcription.\nCurr. Genomics\n7 (8), 497-508. doi:10.2174/138920206779315737\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nMatthews, J., and Gustafsson, J. A. (2003). Estrogen signaling: a subtle balance between ER alpha and ER beta.\nMol. Interv.\n3 (5), 281-292. doi:10.1124/mi.3.5.281\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/1369", "#/texts/1370", "#/texts/1371", "#/texts/1372", "#/texts/1373", "#/texts/1374", "#/texts/1375", "#/texts/1376", "#/texts/1377", "#/texts/1378", "#/texts/1379", "#/texts/1380", "#/texts/1381", "#/texts/1382", "#/texts/1383", "#/texts/1384", "#/texts/1385", "#/texts/1386", "#/texts/1387", "#/texts/1388", "#/texts/1389", "#/texts/1390", "#/texts/1391", "#/texts/1392", "#/texts/1393", "#/texts/1394", "#/texts/1395", "#/texts/1396", "#/texts/1397", "#/texts/1398", "#/texts/1399", "#/texts/1400", "#/texts/1401", "#/texts/1402", "#/texts/1403", "#/texts/1404", "#/texts/1405", "#/texts/1406", "#/texts/1407", "#/texts/1408", "#/texts/1409", "#/texts/1410"], "page_nos": [], "uuid": "cf858608-2ed7-44f2-bf4c-be821aeeb23d"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 54, "source_chunk_idxs": [58], "num_tokens": 448, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nReferences\nMauvais-Jarvis, F., Clegg, D. J., and Hevener, A. L. (2013). The role of estrogens in control of energy balance and glucose homeostasis.\nEndocr. Rev.\n34 (3), 309-338. doi:10.1210/er.2012-1055\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nMcCullough, L. D., Blizzard, K., Simpson, E. R., Oz, O. K., and Hurn, P. D. (2003). Aromatase cytochrome P450 and extragonadal estrogen play a role in ischemic neuroprotection.\nJ. Neurosci.\n23 (25), 8701-8705. doi:10.1523/JNEUROSCI.23-25-08701.2003\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nMcEwen, B. S., Gould, E., Orchinik, M., Weiland, N. G., and Woolley, C. S. (1995). Oestrogens and the structural and functional plasticity of neurons: implications for memory, ageing and neurodegenerative processes.\nCiba Found. Symp.\n191, 52-73. doi:10.1002/9780470514757.ch4\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nMcEwen, B. S., and Woolley, C. S. (1994). Estradiol and progesterone regulate neuronal structure and synaptic connectivity in adult as well as developing brain.\nExp. Gerontol.\n29 (3-4), 431-436. doi:10.1016/0531-5565(94)90022-1\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/1411", "#/texts/1412", "#/texts/1413", "#/texts/1414", "#/texts/1415", "#/texts/1416", "#/texts/1417", "#/texts/1418", "#/texts/1419", "#/texts/1420", "#/texts/1421", "#/texts/1422", "#/texts/1423", "#/texts/1424", "#/texts/1425", "#/texts/1426", "#/texts/1427", "#/texts/1428", "#/texts/1429", "#/texts/1430", "#/texts/1431", "#/texts/1432", "#/texts/1433", "#/texts/1434", "#/texts/1435", "#/texts/1436", "#/texts/1437", "#/texts/1438", "#/texts/1439", "#/texts/1440", "#/texts/1441", "#/texts/1442"], "page_nos": [], "uuid": "e036d0fb-f2fc-4ac1-84d4-d3fb2345e9ae"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 55, "source_chunk_idxs": [59], "num_tokens": 476, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nReferences\nMcGill Percy, K. C., Liu, Z., and Qi, X. (2025). Mitochondrial dysfunction in Alzheimer's disease: guiding the path to targeted therapies.\nNeurotherapeutics\n22 (3), e00525. doi:10.1016/j.neurot.2025.e00525\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nMeyer, M. R., Prossnitz, E. R., and Barton, M. (2011). GPER/GPR30 and regulation of vascular tone and blood pressure.\nImmunol. Endocr. Metab. Agents Med. Chem.\n11 (4), 255-261. doi:10.2174/1871522211108040255\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nMiller, V. M. (2012). In pursuit of scientific excellence: sex matters.\nAdv. Physiol. Educ.\n36 (2), 83-84. doi:10.1152/advan.00039.2012\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nMitra, S. W., Hoskin, E., Yudkovitz, J., Pear, L., Wilkinson, H. A., Hayashi, S., et al. (2003). Immunolocalization of estrogen receptor beta in the mouse brain: comparison with estrogen receptor alpha.\nEndocrinology\n144 (5), 2055-2067. doi:10.1210/en.2002-221069\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nMittal, K., and Katare, D. P. (2016). Shared links between type 2 diabetes mellitus and Alzheimer's disease: a review.\nDiabetes Metab. Syndr.\n10 (2 Suppl. 1), S144-S149. doi:10.1016/j.dsx.2016.01.021\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/1443", "#/texts/1444", "#/texts/1445", "#/texts/1446", "#/texts/1447", "#/texts/1448", "#/texts/1449", "#/texts/1450", "#/texts/1451", "#/texts/1452", "#/texts/1453", "#/texts/1454", "#/texts/1455", "#/texts/1456", "#/texts/1457", "#/texts/1458", "#/texts/1459", "#/texts/1460", "#/texts/1461", "#/texts/1462", "#/texts/1463", "#/texts/1464", "#/texts/1465", "#/texts/1466", "#/texts/1467", "#/texts/1468", "#/texts/1469", "#/texts/1470", "#/texts/1471", "#/texts/1472", "#/texts/1473", "#/texts/1474", "#/texts/1475", "#/texts/1476", "#/texts/1477", "#/texts/1478", "#/texts/1479", "#/texts/1480", "#/texts/1481", "#/texts/1482"], "page_nos": [], "uuid": "ff6de76d-7d72-4f01-b843-1a0b46215905"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 56, "source_chunk_idxs": [60], "num_tokens": 481, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nReferences\nMojsov, S., Weir, G. C., and Habener, J. F. (1987). Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas.\nJ. Clin. Invest\n79 (2), 616-619. doi:10.1172/JCI112855\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nMonteiro, C., Toth, B., Brunstein, F., Bobbala, A., Datta, S., Ceniceros, R., et al. (2023). Randomized phase II study of the safety and efficacy of semorinemab in participants with mild-to-moderate alzheimer disease: lauriet.\nNeurology\n101 (14), e1391-e1401. doi:10.1212/WNL.0000000000207663\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nMontero-Odasso, M., Ismail, Z., and Livingston, G. (2020). One third of dementia cases can be prevented within the next 25 years by tackling risk factors. The case \"for\" and \"against\".\nAlzheimers Res. Ther.\n12 (1), 81. doi:10.1186/s13195-020-00646-x\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nMukai, H., Kimoto, T., Hojo, Y., Kawato, S., Murakami, G., Higo, S., et al. (2010). Modulation of synaptic plasticity by brain estrogen in the hippocampus.\nBiochim. Biophys. Acta\n1800 (10), 1030-1044. doi:10.1016/j.bbagen.2009.11.002\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/1483", "#/texts/1484", "#/texts/1485", "#/texts/1486", "#/texts/1487", "#/texts/1488", "#/texts/1489", "#/texts/1490", "#/texts/1491", "#/texts/1492", "#/texts/1493", "#/texts/1494", "#/texts/1495", "#/texts/1496", "#/texts/1497", "#/texts/1498", "#/texts/1499", "#/texts/1500", "#/texts/1501", "#/texts/1502", "#/texts/1503", "#/texts/1504", "#/texts/1505", "#/texts/1506", "#/texts/1507", "#/texts/1508", "#/texts/1509", "#/texts/1510", "#/texts/1511", "#/texts/1512", "#/texts/1513", "#/texts/1514"], "page_nos": [], "uuid": "114849c0-e24f-4bb3-91ca-2dfb60944547"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 57, "source_chunk_idxs": [61], "num_tokens": 492, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nReferences\nNa, W., Lee, J. Y., Kim, W. S., Yune, T. Y., and Ju, B. G. (2015). 17\u03b2-Estradiol ameliorates tight junction disruption via repression of MMP transcription.\nMol. Endocrinol.\n29 (9), 1347-1361. doi:10.1210/ME.2015-1124\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nNeha, , and Parvez, S. (2023). Emerging therapeutics agents and recent advances in drug repurposing for Alzheimer's disease.\nAgeing Res. Rev.\n85, 101815. doi:10.1016/j.arr.2022.101815\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nNeth, B. J., and Craft, S. (2017). Insulin resistance and Alzheimer's disease: bioenergetic linkages.\nFront. Aging Neurosci.\n9, 345. doi:10.3389/fnagi.2017.00345\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nNeu, S. C., Pa, J., Kukull, W., Beekly, D., Kuzma, A., Gangadharan, P., et al. (2017). Apolipoprotein E genotype and sex risk factors for alzheimer disease: a meta-analysis.\nJAMA Neurol.\n74 (10), 1178-1189. doi:10.1001/jamaneurol.2017.2188\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nNilsen, J., Irwin, R. W., Gallaher, T. K., and Brinton, R. D. (2007). Estradiol\nin vivo\nregulation of brain mitochondrial proteome.\nJ. Neurosci.\n27 (51), 14069-14077. doi:10.1523/JNEUROSCI.4391-07.2007\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/1515", "#/texts/1516", "#/texts/1517", "#/texts/1518", "#/texts/1519", "#/texts/1520", "#/texts/1521", "#/texts/1522", "#/texts/1523", "#/texts/1524", "#/texts/1525", "#/texts/1526", "#/texts/1527", "#/texts/1528", "#/texts/1529", "#/texts/1530", "#/texts/1531", "#/texts/1532", "#/texts/1533", "#/texts/1534", "#/texts/1535", "#/texts/1536", "#/texts/1537", "#/texts/1538", "#/texts/1539", "#/texts/1540", "#/texts/1541", "#/texts/1542", "#/texts/1543", "#/texts/1544", "#/texts/1545", "#/texts/1546", "#/texts/1547", "#/texts/1548", "#/texts/1549", "#/texts/1550", "#/texts/1551", "#/texts/1552", "#/texts/1553", "#/texts/1554", "#/texts/1555", "#/texts/1556"], "page_nos": [], "uuid": "c883976a-f665-4e09-b34c-16e53d60857b"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 58, "source_chunk_idxs": [62], "num_tokens": 437, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nReferences\nNilsson, B. O., Olde, B., and Leeb-Lundberg, L. M. (2011). G protein-coupled oestrogen receptor 1 (GPER1)/GPR30: a new player in cardiovascular and metabolic oestrogenic signalling.\nBr. J. Pharmacol.\n163 (6), 1131-1139. doi:10.1111/j.1476-5381.2011.01235.x\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nNorgaard, C. H., Friedrich, S., Hansen, C. T., Gerds, T., Ballard, C., Moller, D. V., et al. (2022). Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers.\nAlzheimers Dement. (N Y)\n8 (1), e12268. doi:10.1002/trc2.12268\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nNotkola, I. L., Sulkava, R., Pekkanen, J., Erkinjuntti, T., Ehnholm, C., Kivinen, P., et al. (1998). Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease.\nNeuroepidemiology\n17 (1), 14-20. doi:10.1159/000026149\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nOMS (2021).\nGlobal status report on the public health response to dementia: executive summary\n. Editor D.o.M.H.a.S.U.W.H. Geneva: World Health Organization .\nGoogle Scholar", "doc_items_refs": ["#/texts/1557", "#/texts/1558", "#/texts/1559", "#/texts/1560", "#/texts/1561", "#/texts/1562", "#/texts/1563", "#/texts/1564", "#/texts/1565", "#/texts/1566", "#/texts/1567", "#/texts/1568", "#/texts/1569", "#/texts/1570", "#/texts/1571", "#/texts/1572", "#/texts/1573", "#/texts/1574", "#/texts/1575", "#/texts/1576", "#/texts/1577", "#/texts/1578", "#/texts/1579", "#/texts/1580", "#/texts/1581", "#/texts/1582", "#/texts/1583", "#/texts/1584"], "page_nos": [], "uuid": "f115badd-6695-4cca-8e38-c43387c16f06"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 59, "source_chunk_idxs": [63], "num_tokens": 440, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nReferences\nPaidi, R. K., Nthenge-Ngumbau, D. N., Singh, R., Kankanala, T., Mehta, H., and Mohanakumar, K. P. (2015). Mitochondrial deficits accompany cognitive decline following single bilateral intracerebroventricular streptozotocin.\nCurr. Alzheimer Res.\n12 (8), 785-795. doi:10.2174/1567205012666150710112618\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nPeggion, C., Cali, T., and Brini, M. (2024). Mitochondria dysfunction and neuroinflammation in neurodegeneration: who comes first?\nAntioxidants (Basel)\n13 (2), 240. doi:10.3390/antiox13020240\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nPenke, B., Paragi, G., Gera, J., Berkecz, R., Kovacs, Z., Crul, T., et al. (2018). The role of lipids and membranes in the pathogenesis of Alzheimer's disease: a comprehensive view.\nCurr. Alzheimer Res.\n15 (13), 1191-1212. doi:10.2174/1567205015666180911151716\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nPeralta, M., and Lizcano, F. (2024). Endocrine disruptors and metabolic changes: impact on puberty control.\nEndocr. Pract.\n30 (4), 384-397. doi:10.1016/j.eprac.2024.01.006\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/1585", "#/texts/1586", "#/texts/1587", "#/texts/1588", "#/texts/1589", "#/texts/1590", "#/texts/1591", "#/texts/1592", "#/texts/1593", "#/texts/1594", "#/texts/1595", "#/texts/1596", "#/texts/1597", "#/texts/1598", "#/texts/1599", "#/texts/1600", "#/texts/1601", "#/texts/1602", "#/texts/1603", "#/texts/1604", "#/texts/1605", "#/texts/1606", "#/texts/1607", "#/texts/1608", "#/texts/1609", "#/texts/1610", "#/texts/1611", "#/texts/1612", "#/texts/1613", "#/texts/1614", "#/texts/1615", "#/texts/1616"], "page_nos": [], "uuid": "1c6de1af-69c2-46f4-a3b2-e827956f9e95"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 60, "source_chunk_idxs": [64], "num_tokens": 443, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nReferences\nRazmara, A., Sunday, L., Stirone, C., Wang, X. B., Krause, D. N., Duckles, S. P., et al. (2008). Mitochondrial effects of estrogen are mediated by estrogen receptor alpha in brain endothelial cells.\nJ. Pharmacol. Exp. Ther.\n325 (3), 782-790. doi:10.1124/jpet.107.134072\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nReich, N., and Holscher, C. (2022). The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: an in-depth review.\nFront. Neurosci.\n16, 970925. doi:10.3389/fnins.2022.970925\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nReiman, E. M., Arboleda-Velasquez, J. F., Quiroz, Y. T., Huentelman, M. J., Beach, T. G., Caselli, R. J., et al. (2020). Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes from a 5,000-person neuropathological study.\nNat. Commun.\n11 (1), 667. doi:10.1038/s41467-019-14279-8\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nReport, A.S.A.(2024). 2024 Alzheimer's disease facts and figures.\nAlzheimers Dement\n. 20(5). 3708-3821. doi:10.1002/alz.13809\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/1617", "#/texts/1618", "#/texts/1619", "#/texts/1620", "#/texts/1621", "#/texts/1622", "#/texts/1623", "#/texts/1624", "#/texts/1625", "#/texts/1626", "#/texts/1627", "#/texts/1628", "#/texts/1629", "#/texts/1630", "#/texts/1631", "#/texts/1632", "#/texts/1633", "#/texts/1634", "#/texts/1635", "#/texts/1636", "#/texts/1637", "#/texts/1638", "#/texts/1639", "#/texts/1640", "#/texts/1641", "#/texts/1642", "#/texts/1643", "#/texts/1644", "#/texts/1645", "#/texts/1646", "#/texts/1647", "#/texts/1648"], "page_nos": [], "uuid": "b349f0dd-83c4-45d7-8bb9-d5bae828f185"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 61, "source_chunk_idxs": [65], "num_tokens": 417, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nReferences\nRichard, J. E., Anderberg, R. H., Goteson, A., Gribble, F. M., Reimann, F., and Skibicka, K. P. (2015). Activation of the GLP-1 receptors in the nucleus of the solitary tract reduces food reward behavior and targets the mesolimbic system.\nPLoS One\n10 (3), e0119034. doi:10.1371/journal.pone.0119034\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nRosenstock, J., Frias, J., Jastreboff, A. M., Du, Y., Lou, J., Gurbuz, S., et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.\nLancet\n402 (10401), 529-544. doi:10.1016/S0140-6736(23)01053-X\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nSachs, S., Bastidas-Ponce, A., Tritschler, S., Bakhti, M., Bottcher, A., Sanchez-Garrido, M. A., et al. (2020). Targeted pharmacological therapy restores beta-cell function for diabetes remission.\nNat. Metab.\n2 (2), 192-209. doi:10.1038/s42255-020-0171-3\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/1649", "#/texts/1650", "#/texts/1651", "#/texts/1652", "#/texts/1653", "#/texts/1654", "#/texts/1655", "#/texts/1656", "#/texts/1657", "#/texts/1658", "#/texts/1659", "#/texts/1660", "#/texts/1661", "#/texts/1662", "#/texts/1663", "#/texts/1664", "#/texts/1665", "#/texts/1666", "#/texts/1667", "#/texts/1668", "#/texts/1669", "#/texts/1670", "#/texts/1671", "#/texts/1672"], "page_nos": [], "uuid": "a99dffe8-390a-4da6-b879-a19f534b1231"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 62, "source_chunk_idxs": [66], "num_tokens": 467, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nReferences\nSanchez-Garrido, M. A., Serrano-Lopez, V., Ruiz-Pino, F., Vazquez, M. J., Rodriguez-Martin, A., Torres, E., et al. (2024). Superior metabolic improvement of polycystic ovary syndrome traits after GLP1-based multi-agonist therapy.\nNat. Commun.\n15 (1), 8498. doi:10.1038/s41467-024-52898-y\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nSchulingkamp, R. J., Pagano, T. C., Hung, D., and Raffa, R. B. (2000). Insulin receptors and insulin action in the brain: review and clinical implications.\nNeurosci. Biobehav Rev.\n24 (8), 855-872. doi:10.1016/s0149-7634(00)00040-3\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nSchwenk, R. W., Baumeier, C., Finan, B., Kluth, O., Brauer, C., Joost, H. G., et al. (2015). GLP-1-oestrogen attenuates hyperphagia and protects from beta cell failure in diabetes-prone New Zealand obese (NZO) mice.\nDiabetologia\n58 (3), 604-614. doi:10.1007/s00125-014-3478-3\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nShi, J., Sabbagh, M. N., and Vellas, B. (2020). Alzheimer's disease beyond amyloid: strategies for future therapeutic interventions.\nBMJ\n371, m3684. doi:10.1136/bmj.m3684\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/1673", "#/texts/1674", "#/texts/1675", "#/texts/1676", "#/texts/1677", "#/texts/1678", "#/texts/1679", "#/texts/1680", "#/texts/1681", "#/texts/1682", "#/texts/1683", "#/texts/1684", "#/texts/1685", "#/texts/1686", "#/texts/1687", "#/texts/1688", "#/texts/1689", "#/texts/1690", "#/texts/1691", "#/texts/1692", "#/texts/1693", "#/texts/1694", "#/texts/1695", "#/texts/1696", "#/texts/1697", "#/texts/1698", "#/texts/1699", "#/texts/1700", "#/texts/1701", "#/texts/1702", "#/texts/1703", "#/texts/1704"], "page_nos": [], "uuid": "c640f51c-4a9c-402c-a02e-b66a624f9e27"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 63, "source_chunk_idxs": [67], "num_tokens": 503, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nReferences\nShimano, H., and Sato, R. (2017). SREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology.\nNat. Rev. Endocrinol.\n13 (12), 710-730. doi:10.1038/nrendo.2017.91\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nShirazi, R. H., Dickson, S. L., and Skibicka, K. P. (2013). Gut peptide GLP-1 and its analogue, Exendin-4, decrease alcohol intake and reward.\nPLoS One\n8 (4), e61965. doi:10.1371/journal.pone.0061965\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nSilva, D. F., Esteves, A. R., Oliveira, C. R., and Cardoso, S. M. (2017). Mitochondrial metabolism power SIRT2-dependent deficient traffic causing alzheimer's-disease related pathology.\nMol. Neurobiol.\n54 (6), 4021-4040. doi:10.1007/s12035-016-9951-x\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nStirone, C., Boroujerdi, A., Duckles, S. P., and Krause, D. N. (2005). Estrogen receptor activation of phosphoinositide-3 kinase, akt, and nitric oxide signaling in cerebral blood vessels: rapid and long-term effects.\nMol. Pharmacol.\n67 (1), 105-113. doi:10.1124/mol.104.004465\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nStoccoro, A., Siciliano, G., Migliore, L., and Coppede, F. (2017). Decreased methylation of the mitochondrial D-loop region in late-onset alzheimer's disease.\nJ. Alzheimers Dis.\n59 (2), 559-564. doi:10.3233/JAD-170139", "doc_items_refs": ["#/texts/1705", "#/texts/1706", "#/texts/1707", "#/texts/1708", "#/texts/1709", "#/texts/1710", "#/texts/1711", "#/texts/1712", "#/texts/1713", "#/texts/1714", "#/texts/1715", "#/texts/1716", "#/texts/1717", "#/texts/1718", "#/texts/1719", "#/texts/1720", "#/texts/1721", "#/texts/1722", "#/texts/1723", "#/texts/1724", "#/texts/1725", "#/texts/1726", "#/texts/1727", "#/texts/1728", "#/texts/1729", "#/texts/1730", "#/texts/1731", "#/texts/1732", "#/texts/1733", "#/texts/1734", "#/texts/1735", "#/texts/1736", "#/texts/1737", "#/texts/1738", "#/texts/1739"], "page_nos": [], "uuid": "808f57b8-5ebd-4c4d-857f-1b8e342ac779"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 64, "source_chunk_idxs": [68], "num_tokens": 424, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nReferences\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nStojakovic, A., Trushin, S., Sheu, A., Khalili, L., Chang, S. Y., Li, X., et al. (2021). Partial inhibition of mitochondrial complex I ameliorates Alzheimer's disease pathology and cognition in APP/PS1 female mice.\nCommun. Biol.\n4 (1), 61. doi:10.1038/s42003-020-01584-y\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nSuzuki, S., Brown, C. M., and Wise, P. M. (2006). Mechanisms of neuroprotection by estrogen.\nEndocrine\n29 (2), 209-215. doi:10.1385/ENDO:29:2:209\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nTatar, M., Bartke, A., and Antebi, A. (2003). The endocrine regulation of aging by insulin-like signals.\nScience\n299 (5611), 1346-1351. doi:10.1126/science.1081447\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nTerao, I., and Kodama, W. (2024). Comparative efficacy, tolerability, and acceptability of donanemab, lecanemab, aducanumab, melatonin, and aerobic exercise for a short time on cognitive function in mild cognitive impairment and mild Alzheimer's disease: a systematic review and network meta-analysis.\nJ. Alzheimers Dis.\n98 (3), 825-835. doi:10.3233/JAD-230911\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/1740", "#/texts/1741", "#/texts/1742", "#/texts/1743", "#/texts/1744", "#/texts/1745", "#/texts/1746", "#/texts/1747", "#/texts/1748", "#/texts/1749", "#/texts/1750", "#/texts/1751", "#/texts/1752", "#/texts/1753", "#/texts/1754", "#/texts/1755", "#/texts/1756", "#/texts/1757", "#/texts/1758", "#/texts/1759", "#/texts/1760", "#/texts/1761", "#/texts/1762", "#/texts/1763", "#/texts/1764", "#/texts/1765", "#/texts/1766", "#/texts/1767", "#/texts/1768", "#/texts/1769", "#/texts/1770", "#/texts/1771", "#/texts/1772", "#/texts/1773", "#/texts/1774", "#/texts/1775", "#/texts/1776"], "page_nos": [], "uuid": "b4572e18-0e5d-4a47-9314-170f22bf576b"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 65, "source_chunk_idxs": [69], "num_tokens": 450, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nReferences\nTian, X., Gao, Y., Kong, M., Zhao, L., Xing, E., Sun, Q., et al. (2023). GLP-1 receptor agonist protects palmitate-induced insulin resistance in skeletal muscle cells by up-regulating sestrin2 to promote autophagy.\nSci. Rep.\n13 (1), 9446. doi:10.1038/s41598-023-36602-6\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nTian, Z., Fan, J., Zhao, Y., Bi, S., Si, L., and Liu, Q. (2013). Estrogen receptor beta treats Alzheimer's disease.\nNeural Regen. Res.\n8 (5), 420-426. doi:10.3969/j.issn.1673-5374.2013.05.005\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nTiano, J. P., Tate, C. R., Yang, B. S., DiMarchi, R., and Mauvais-Jarvis, F. (2015). Effect of targeted estrogen delivery using glucagon-like peptide-1 on insulin secretion, insulin sensitivity and glucose homeostasis.\nSci. Rep.\n5, 10211. doi:10.1038/srep10211\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nTurton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M., Meeran, K., et al. (1996). A role for glucagon-like peptide-1 in the central regulation of feeding.\nNature\n379 (6560), 69-72. doi:10.1038/379069a0\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/1777", "#/texts/1778", "#/texts/1779", "#/texts/1780", "#/texts/1781", "#/texts/1782", "#/texts/1783", "#/texts/1784", "#/texts/1785", "#/texts/1786", "#/texts/1787", "#/texts/1788", "#/texts/1789", "#/texts/1790", "#/texts/1791", "#/texts/1792", "#/texts/1793", "#/texts/1794", "#/texts/1795", "#/texts/1796", "#/texts/1797", "#/texts/1798", "#/texts/1799", "#/texts/1800", "#/texts/1801", "#/texts/1802", "#/texts/1803", "#/texts/1804", "#/texts/1805", "#/texts/1806", "#/texts/1807", "#/texts/1808"], "page_nos": [], "uuid": "aacb4993-4e42-4e78-9fd0-6e94325b20d7"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 66, "source_chunk_idxs": [70], "num_tokens": 450, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nReferences\nUlhaq, Z. S., and Garcia, C. P. (2021). Estrogen receptor beta (ESR2) gene polymorphism and susceptibility to dementia.\nActa Neurol. Belg\n121 (5), 1281-1293. doi:10.1007/s13760-020-01360-z\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nValdes-Sustaita, B., Estrada-Camarena, E., Gonzalez-Trujano, M. E., and Lopez-Rubalcava, C. (2021). Estrogen receptors-beta and serotonin mediate the antidepressant-like effect of an aqueous extract of pomegranate in ovariectomized rats.\nNeurochem. Int.\n142, 104904. doi:10.1016/j.neuint.2020.104904\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nvan Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., et al. (2023). Lecanemab in early Alzheimer's disease.\nN. Engl. J. Med.\n388 (1), 9-21. doi:10.1056/NEJMoa2212948\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nVargas, K. G., Milic, J., Zaciragic, A., Wen, K. X., Jaspers, L., Nano, J., et al. (2016). The functions of estrogen receptor beta in the female brain: a systematic review.\nMaturitas\n93, 41-57. doi:10.1016/j.maturitas.2016.05.014\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/1809", "#/texts/1810", "#/texts/1811", "#/texts/1812", "#/texts/1813", "#/texts/1814", "#/texts/1815", "#/texts/1816", "#/texts/1817", "#/texts/1818", "#/texts/1819", "#/texts/1820", "#/texts/1821", "#/texts/1822", "#/texts/1823", "#/texts/1824", "#/texts/1825", "#/texts/1826", "#/texts/1827", "#/texts/1828", "#/texts/1829", "#/texts/1830", "#/texts/1831", "#/texts/1832", "#/texts/1833", "#/texts/1834", "#/texts/1835", "#/texts/1836", "#/texts/1837", "#/texts/1838", "#/texts/1839", "#/texts/1840"], "page_nos": [], "uuid": "b9b9206a-8b88-4276-94fe-ef61395c78b2"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 67, "source_chunk_idxs": [71], "num_tokens": 505, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nReferences\nVeliskova, J., and Desantis, K. A. (2013). Sex and hormonal influences on seizures and epilepsy.\nHorm. Behav.\n63 (2), 267-277. doi:10.1016/j.yhbeh.2012.03.018\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nVogel, H., Wolf, S., Rabasa, C., Rodriguez-Pacheco, F., Babaei, C. S., Stober, F., et al. (2016). GLP-1 and estrogen conjugate acts in the supramammillary nucleus to reduce food-reward and body weight.\nNeuropharmacology\n110 (Pt A), 396-406. doi:10.1016/j.neuropharm.2016.07.039\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nVolgman, A. S., Koschinsky, M. L., Mehta, A., and Rosenson, R. S. (2024). Genetics and pathophysiological mechanisms of lipoprotein(a)-associated cardiovascular risk.\nJ. Am. Heart Assoc.\n13 (12), e033654. doi:10.1161/JAHA.123.033654\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nWalsh, S., Merrick, R., Milne, R., and Brayne, C. (2021). Aducanumab for Alzheimer's disease?\nBMJ\n374, n1682. doi:10.1136/bmj.n1682\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nWang, J., Xiong, S., Xie, C., Markesbery, W. R., and Lovell, M. A. (2005). Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease.\nJ. Neurochem.\n93 (4), 953-962. doi:10.1111/j.1471-4159.2005.03053.x", "doc_items_refs": ["#/texts/1841", "#/texts/1842", "#/texts/1843", "#/texts/1844", "#/texts/1845", "#/texts/1846", "#/texts/1847", "#/texts/1848", "#/texts/1849", "#/texts/1850", "#/texts/1851", "#/texts/1852", "#/texts/1853", "#/texts/1854", "#/texts/1855", "#/texts/1856", "#/texts/1857", "#/texts/1858", "#/texts/1859", "#/texts/1860", "#/texts/1861", "#/texts/1862", "#/texts/1863", "#/texts/1864", "#/texts/1865", "#/texts/1866", "#/texts/1867", "#/texts/1868", "#/texts/1869", "#/texts/1870", "#/texts/1871", "#/texts/1872", "#/texts/1873", "#/texts/1874", "#/texts/1875"], "page_nos": [], "uuid": "bd2f58be-cb02-4ccd-987e-3f396bad7059"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 68, "source_chunk_idxs": [72], "num_tokens": 461, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nReferences\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nWarner, M., and Gustafsson, J. A. (2015). Estrogen receptor \u03b2 and Liver X receptor \u03b2: biology and therapeutic potential in CNS diseases.\nMol. Psychiatry\n20 (1), 18-22. doi:10.1038/mp.2014.23\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nWeidling, I. W., Wilkins, H. M., Koppel, S. J., Hutfles, L., Wang, X., Kalani, A., et al. (2020). Mitochondrial DNA manipulations affect tau oligomerization.\nJ. Alzheimers Dis.\n77 (1), 149-163. doi:10.3233/JAD-200286\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nWeiser, M. J., Foradori, C. D., and Handa, R. J. (2008). Estrogen receptor beta in the brain: from form to function.\nBrain Res. Rev.\n57 (2), 309-320. doi:10.1016/j.brainresrev.2007.05.013\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nYaribeygi, H., Rashidy-Pour, A., Atkin, S. L., Jamialahmadi, T., and Sahebkar, A. (2021). GLP-1 mimetics and cognition.\nLife Sci.\n264, 118645. doi:10.1016/j.lfs.2020.118645\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nYin, F. (2023). Lipid metabolism and Alzheimer's disease: clinical evidence, mechanistic link and therapeutic promise.\nFEBS J.\n290 (6), 1420-1453. doi:10.1111/febs.16344\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/1876", "#/texts/1877", "#/texts/1878", "#/texts/1879", "#/texts/1880", "#/texts/1881", "#/texts/1882", "#/texts/1883", "#/texts/1884", "#/texts/1885", "#/texts/1886", "#/texts/1887", "#/texts/1888", "#/texts/1889", "#/texts/1890", "#/texts/1891", "#/texts/1892", "#/texts/1893", "#/texts/1894", "#/texts/1895", "#/texts/1896", "#/texts/1897", "#/texts/1898", "#/texts/1899", "#/texts/1900", "#/texts/1901", "#/texts/1902", "#/texts/1903", "#/texts/1904", "#/texts/1905", "#/texts/1906", "#/texts/1907", "#/texts/1908", "#/texts/1909", "#/texts/1910", "#/texts/1911", "#/texts/1912", "#/texts/1913", "#/texts/1914", "#/texts/1915", "#/texts/1916", "#/texts/1917", "#/texts/1918", "#/texts/1919", "#/texts/1920"], "page_nos": [], "uuid": "8744e33c-2b2d-4780-92dc-86771ef17ceb"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 69, "source_chunk_idxs": [73], "num_tokens": 435, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nReferences\nZhang, X., Zhou, K., Wang, R., Cui, J., Lipton, S. A., Liao, F. F., et al. (2007). Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation.\nJ. Biol. Chem.\n282 (15), 10873-10880. doi:10.1074/jbc.M608856200\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nZhao, Z., Sagare, A. P., Ma, Q., Halliday, M. R., Kong, P., Kisler, K., et al. (2015). Central role for PICALM in amyloid-beta blood-brain barrier transcytosis and clearance.\nNat. Neurosci.\n18 (7), 978-987. doi:10.1038/nn.4025\nPubMed Abstract\n|\nCrossRef Full Text\n|\nGoogle Scholar\nKeywords: Alzheimerr\u2032s disease, GLP-1 agonists, estrogens, prevention, metabolism\nCitation: Lizcano F, Sanabria D and Aviles E (2025) Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens.\nFront. Mol. Biosci.\n12:1622186. doi: 10.3389/fmolb.2025.1622186\nReceived: 02 May 2025; Accepted: 02 June 2025; Published: 26 June 2025.\nEdited by:\nRoberta Marongiu\n, Cornell University, United States\nReviewed by:\nLarance Ronsard\n, Ragon Institute, United States\nJorge Felipe Argenta Model\n, Federal University of Rio Grande do Sul, Brazil", "doc_items_refs": ["#/texts/1921", "#/texts/1922", "#/texts/1923", "#/texts/1924", "#/texts/1925", "#/texts/1926", "#/texts/1927", "#/texts/1928", "#/texts/1929", "#/texts/1930", "#/texts/1931", "#/texts/1932", "#/texts/1933", "#/texts/1934", "#/texts/1935", "#/texts/1936", "#/texts/1937", "#/texts/1938", "#/texts/1939", "#/texts/1940", "#/texts/1941", "#/texts/1942", "#/texts/1943", "#/texts/1944", "#/texts/1945", "#/texts/1946", "#/texts/1947", "#/texts/1948", "#/texts/1949"], "page_nos": [], "uuid": "e02fc67b-d5c2-4f93-8dc1-88cccd169821"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 70, "source_chunk_idxs": [74], "num_tokens": 447, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nReferences\nCopyright \u00a9 2025 Lizcano, Sanabria and Aviles. This is an open-access article distributed under the terms of the\nCreative Commons Attribution License (CC BY).\nThe use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.\n*Correspondence: Fernando Lizcano, ZmVybmFuZG9sbEB1bmlzYWJhbmEuZWR1LmNv\nDisclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.\nDownload article\n- Download PDF\n- ReadCube\n- epub\n- XML\nShare on\nExport citation\n- EndNote\n- Reference Manager\n- Simple Text file\n- BibTex\n2,419 Total views 721 Downloads Citation numbers are available from Dimensions\nView article impact\nView altmetric score\nShare on\nEdited by\nR M Roberta  Marongiu\nReviewed by\nL R Larance  Ronsard\nJ F Jorge  Felipe Argenta Model\nTable of contents\n- Abstract\n- 1 Introduction\n- 2 Neuronal metabolism and Alzheimer's disease\n- 3 The mitochondrial theory of Alzheimer's disease\n- 4 Role of estrogens in neuronal function\n- 5 Estrogen effects on mitochondrial function\n- 6 Do GLP-1 receptor agonists influence mitochondria and Alzheimer's disease?\n- 7 Could dual agonism of estrogen and GLP-1 influence Alzheimer's disease prevention?\n- 8 Conclusion\n- Author contributions\n- Funding\n- Conflict of interest\n- Generative AI statement\n- Publisher's note\n- References\nExport citation\n- EndNote\n- Reference Manager\n- Simple Text file\n- BibTex\nCheck for updates\nFrontiers' impact", "doc_items_refs": ["#/texts/1950", "#/texts/1951", "#/texts/1952", "#/texts/1953", "#/texts/1954", "#/texts/1955", "#/texts/1956", "#/texts/1957", "#/texts/1958", "#/texts/1959", "#/texts/1960", "#/texts/1961", "#/texts/1962", "#/texts/1963", "#/texts/1964", "#/texts/1965", "#/texts/1966", "#/texts/1967", "#/texts/1968", "#/texts/1969", "#/texts/1970", "#/texts/1971", "#/texts/1972", "#/texts/1973", "#/texts/1974", "#/texts/1975", "#/texts/1976", "#/texts/1977", "#/texts/1978", "#/texts/1979", "#/texts/1980", "#/texts/1981", "#/texts/1982", "#/texts/1983", "#/texts/1984", "#/texts/1985", "#/texts/1986", "#/texts/1987", "#/texts/1988", "#/texts/1989", "#/texts/1990", "#/texts/1991", "#/texts/1992", "#/texts/1993", "#/texts/1994", "#/texts/1995", "#/texts/1996", "#/texts/1997"], "page_nos": [], "uuid": "e66aee3c-bd29-4a2a-94c8-dd4c1e6252cf"}
{"doc_id": "2025__Hormonal_modulation_mitochondria_and_Alzheimers_prevention_the_role_of_GLP-1_ago__W4411640834", "source_path": "<redacted:source_path>", "chunk_id": 71, "source_chunk_idxs": [75], "num_tokens": 109, "text": "Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens\nArticles published with Frontiers have received 12 million total citations\nYour research is the real superpower - learn how we maximise its impact through our leading community journals\nExplore our impact metrics\nSupplementary Material\nDownload article\nDownload\n- Download PDF\n- ReadCube\n- epub\n- XML\n- Guidelines\n- Explore\n- Outreach\n- Connect\nFollow us\n\u00a9 2025 Frontiers Media S.A. All rights reserved\nPrivacy policy\n|\nTerms and conditions", "doc_items_refs": ["#/texts/1999", "#/texts/2000", "#/texts/2001", "#/texts/2002", "#/texts/2003", "#/texts/2004", "#/texts/2005", "#/texts/2006", "#/texts/2007", "#/texts/2008", "#/texts/2009", "#/texts/2010", "#/texts/2011", "#/texts/2012", "#/texts/2013", "#/texts/2014", "#/texts/2015", "#/texts/2016"], "page_nos": [], "uuid": "bcb0cc67-c929-48a2-8602-2e18c2aee819"}
